Apolipoprotein
CIII: 42 years old and even more interesting
Arterioscler
Thromb Vasc Biol 2011;31:471-3 - Abstract e diapositive
Transcriptional activation of apolipoprotein CIII expression by glucose may contribute
to diabetic dyslipidemia
Arterioscler
Thromb Vasc Biol 2011;31:513-9 - Abstract e diapositive
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in
the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic
Events (ILLUMINATE) trial
Circulation
2011;124:555-562 - Abstract e diapositive
Cholesterol
efflux capacity, high-density lipoprotein function, and atherosclerosis
N
Engl J Med 2011;364:127-35 - Abstract e diapositive
Role
of oxidized low density lipoproteins and free fatty acids in the pathogenesis
of glomerulopathy and tubulointerstitial lesions in type 2 diabetes
Nutr
Metab Cardiovasc Dis 2011;21:79-85 - Abstract e diapositive
The role
of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular
events in patients with atherosclerotic cardiovascular disease and optimally treated
low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis
Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on
Global Health outcomes (AIM-HIGH)
Am Heart
J 2011;161:471-477 - Abstract e diapositive
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular
events in patients with atherosclerotic cardiovascular disease and optimally treated
low-density lipoprotein cholesterol: baseline characteristics of study participants.
The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides:
impact on Global Health outcomes (AIM-HIGH) trial
Am Heart
J 2011;161:538-43 - Abstract e diapositive
Nicotinic acid inhibits progression of atherosclerosis in mice through its
receptor GPR109A expressed by immune cells
J
Clin Invest 2011;121:1163-73 - Abstract e diapositive
The effects
of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic
kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled
trial
Lancet
2011;Epub 9 June - Abstract e diapositive
Ezetimibe
improves postprandial hyperlipemia and its induced endothelial dysfunction
Atherosclerosis
Epub 2011 Apr 22 - Abstract e diapositive
Cardiovascular event reduction and adverse events among subjects attaining
low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER
trial (Justification for the Use of Statins in Prevention: an Intervention Trial
Evaluating Rosuvastatin)
J
Am Coll Cardiol 2011;57:1666-75 - Abstract e diapositive
Benefit
of Intensive Statin Therapy in Women: Results From PROVE IT-TIMI 22
Circ Cardiovasc Qual Outcomes 2011;4:328-336 - Abstract e diapositive
C-reactive
protein concentration and the vascular benefits of statin therapy: an analysis
of 20,536 patients in the Heart Protection Study
Lancet 2011;377:469-76 - Abstract e diapositive
Association
between C reactive protein and coronary heart disease: mendelian randomisation
analysis based on individual participant data
BMJ 2011;342:d548 - Abstract e diapositive
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
N Engl J Med 2011;364:127-35 - Abstract e diapositive
National,
regional, and global trends in body-mass index since 1980: systematic analysis
of health examination surveys and epidemiological studies with 960 country-years
and 9·1 million participants
Lancet
2011;377:557-67 - Abstract e diapositive
National, regional, and global trends in systolic blood pressure since 1980:
systematic analysis of health examination surveys and epidemiological studies
with 786 country-years and 5·4 million participants
Lancet
2011;377:568-77 - Abstract e diapositive
National,
regional, and global trends in serum total cholesterol since 1980: systematic
analysis of health examination surveys and epidemiological studies with 321 country-years
and 3·0 million participants
Lancet
2011;377:578-86 - Abstract e diapositive
Population-based
health-economic evaluation of the secondary prevention of coronary heart disease
in Finland
Curr
Med Res Opin 2010;26:25-36 - Abstract e diapositive
Economic
evaluation of ezetimibe combined with simvastatin for the treatment of primary
hypercholesterolaemia
Neth
Heart J 2011;19:61-67 - Abstract e diapositive
Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the
statin dose in the United Kingdom: findings from the INFORCE study
Value
Health 2010;13:726-347 - Abstract e diapositive
Lipoprotein(a)
as a cardiovascular risk factor: current status
Eur Heart
J 2010;31:2844-53 - Abstract e diapositive
Rosuvastatin for primary prevention in patients with European systematic coronary
risk evaluation risk = 5% or Framingham risk >20%: post hoc analyses of the
JUPITER trial requested by European health authorities
Eur Heart
J 2011;32:75-83 - Abstract e diapositive
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis
of data from 170,000 participants in 26 randomised trials
Lancet
2010;376:1670-81 - Abstract e diapositive
Intensive
lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064
survivors of myocardial infarction: a double-blind randomised trial
Lancet
2010;376:1658-69 - Abstract e diapositive
Cardiovascular
benefit of magnitude of low-density lipoprotein cholesterol reduction: a comparison
of subgroups by age
Circulation
2009;120:1491-7 - Abstract e diapositive
A
systematic review and meta-analysis on the therapeutic equivalence of statins
J
Clin Pharm Ther 2010;35:139-51 - Abstract e diapositive
Cardiovascular
and cancer mortality in very elderly post-myocardial infarction patients receiving
statin treatment
J
Am Coll Cardiol 2010;55:1362-9 - Abstract e diapositive
Effects
of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Lancet
2010 [Epub May 10] - Abstract e diapositive
Statins
and risk of incident diabetes: a collaborative meta-analysis of randomised statin
trials
Lancet
2010;375:735-42 - Abstract e diapositive
Effects
of Combination Lipid Therapy in Type 2 Diabetes Mellitus
N
Engl J Med 2010 [Epub Mar 14] - Abstract e diapositive
Effects
of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus
N
Engl J Med 2010 [Epub Mar 14] - Abstract e diapositive
Effects
of high-dose modified-release nicotinic acid on atherosclerosis and vascular function:
a randomized, placebo-controlled, magnetic resonance imaging study
J
Am Coll Cardiol 2009;54:1787-94 - Abstract e diapositive
Extended-release
niacin or ezetimibe and carotid intima-media thickness
N
Engl J Med 2009;361:2113-22 - Abstract e diapositive
Indices
of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin
J
Clin Endocrinol Metab 2009 [Epub Dec 4] - Abstract e diapositive
Novel and
conventional biomarkers for prediction of incident cardiovascular events in the
community
JAMA
2009;302:49-57 - Abstract e diapositive
Disponibile
su SEFAP l'abstract in italiano
Biomarkers
and Cardiovascular Disease - Determining Causality and Quantifying Contribution
to Risk Assessment
JAMA
2009;302:92-93 - editoriale
CRP, other
biomarkers, not clinically useful to predict CVD risk
Commento
tratto da Theheart.org
Comparison
of C-reactive protein and metabolic syndrome as cardiovascular risk factors in
African-Americans and European-Americans
Am
J Cardiol 2009;103:523-7 - Abstract e diapositive
Use of Framingham
risk score and new biomarkers to predict cardiovascular mortality in older people:
population based observational cohort study
BMJ
2009;338:a3083 - Abstract e diapositive
Homocysteine
may be best predictor of CV risk in elderly
Commento
tratto da Theheart.org
Homocysteine
increases the risk associated with hyperlipidaemia
Eur
J Cardiovasc Prev Rehabil 2009;16:150-5 - Abstract e diapositive
Single versus
combined blood pressure components and risk for cardiovascular disease: the Framingham
Heart Study
Circulation
2009;119:243-50 - Abstract e diapositive
Assessing
Cardiovascular Risk - Should We Discard Diastolic Blood Pressure?
Circulation
2009;119:210-212 - Editoriale
Resistin,
adiponectin, and risk of heart failure the Framingham offspring study
J
Am Coll Cardiol 2009;53:754-62 - Abstract e diapositive
Novel Risk
Factors for Heart Failure: When the Whole May Be Greater Than the Sum of Its Parts
J
Am Coll Cardiol 2009;53:763-4 - Editoriale
Possible
new pathway in heart-failure development
Commento
tratto da Theheart.org
Relationship
of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with
cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy
in patients with acute coronary syndromes: Results from the MIRACL (Myocardial
Ischemia Reduction With Aggressive Cholesterol Lowering) trial
J
Am Coll Cardiol 2009;53:2186-96 - Abstract e diapositive
Lipoprotein(a)
concentration and the risk of coronary heart disease, stroke, and nonvascular
mortality
JAMA
2009;302:412-23 - Abstract e diapositive
Lp(a) is
a causal factor for CVD, but a modest one
Commento
tratto da Theheart.org
Genetically-elevated
Lipoprotein (a) and increased risk of myocardial infarction
JAMA
2009; 301:2331-2339 - Abstract e diapositive
Disponibile
su SEFAP l'abstract in italiano
New data
show that Lp(a) is a causal factor for MI, researchers say
Commento
tratto da Theheart.org
The joint
effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol
on risk: 3510 cases of acute myocardial infarction and 9805 controls
Eur
Heart J 2009 [Epub ahead of print] - Abstract e diapositive
Genetic
Loci associated with C-reactive protein levels and risk of coronary heart disease
JAMA
2009;302:37-48 - Abstract e diapositive
Association
of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid
levels, and coronary risk
JAMA
2008;299:2777-88 - Abstract e diapositive
CETP genes,
metabolic effects, and coronary disease risk
JAMA
2008;299:2795-2796 - Editoriale
Mendelian
randomization. Nature's randomized trial in the post-genome era
JAMA
2009;301:2386-2388 - Editoriale
Mediterranean
diet and incidence of and mortality from coronary heart disease and stroke in
women
Circulation
2009;119:1093-100 - Abstract e diapositive
Commento tratto da Nutrition Foundation
of Italy
Mediterranean diet reduces risk of heart attack, stroke
Commento
tratto da Theheart.org
Anatomy of health effects of mediterranean diet: greek EPIC prospective cohort
study
BMJ
2009;338:b2337 - Abstract e diapositive
Commento
disponibile su Nutrition Foundation of Italy
Moderate wine, little meat, many vegetables may be key mediterranean diet items
linked to longer life
Commento
tratto da Theheart.org
A systematic review of the evidence supporting a causal link between dietary factors
and coronary heart disease
Arch
Intern Med 2009;169:659-69 - Abstract e diapositive
Meta-analysis supports heart-health benefits from a mediterranean diet
Commento
tratto da Theheart.org
The preventable causes of death in the united states: comparative risk assessment
of dietary, lifestyle, and metabolic risk factors
PLoS
Med 2009;6:e1000058 - Abstract e diapositive
Disponibile
su SEFAP l'abstract in italiano
Smoking, high bp cause the most "preventable" deaths in US
Commento
tratto da Theheart.org
Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular
risk factors and level of education.
Br
J Clin Pharmacol 2009;67:355-62 - Abstract e diapositive
The relationship
between reduction in low-density lipoprotein cholesterol by statins and reduction
in risk of cardiovascular outcomes: an updated meta-analysis
Clin Ther 2009;31:236-44 - Abstract e diapositive
Low levels
of low-density lipoprotein cholesterol and blood pressure and progression of coronary
atherosclerosis
J
Am Coll Cardiol 2009;53:1110-5 - Abstract e diapositive
Disponibile
su SEFAP abstract in italiano
Atheroma
volume by intravascular ultrasound as a surrogate for clinical end points
J
Am Coll Cardiol 2009;53:1116-8 - Editoriale
Very low
LDL and normal BP result in slowest progression of atherosclerosis
Commento
tratto da Theheart.org
Effect of
statins on a wide range of health outcomes: a cohort study validated by comparison
with randomized trials
Br
J Clin Pharmacol 2009;67:99-109 - Abstract e diapositive
Disponibile
su SEFAP abstract e tabelle in italiano
The benefits
of statins in people without established cardiovascular disease but with cardiovascular
risk factors: meta-analysis of randomised controlled trials
BMJ 2009;338:b2376 - Abstract e diapositive
New meta-analysis:
Statins of benefit in primary prevention
Commento
tratto da Theheart.org
Continuation
of statin treatment and all-cause mortality: a population-based cohort study
Arch
Intern Med 2009;169:260-8 - Abstract e diapositive
Association
Not Causation
Arch Intern Med 2009;169:1079 - Commento
Statin
adherence associated with lower all-cause mortality, even in primary prevention
Commento
tratto da Theheart.org
Impact
of better adherence to statin agents in the primary prevention of coronary artery
disease
Eur
J Clin Pharmacol 2009 [Epub] - Abstract e diapositive
Lipid
management in the prevention of stroke: review and updated meta-analysis of statins
for stroke prevention
Lancet
Neurol 2009;8:453-63 - Abstract e diapositive
Reducing
LDL cholesterol with statins reduces stroke risk: meta-analysis
Commento
tratto da Theheart.org
Aspirin in the primary and secondary prevention of vascular disease: collaborative
meta-analysis of individual participant data from randomised trials
Lancet
2009;373:1849-60 - Abstract e diapositive
Disponibile
su SEFAP abstract in italiano
Aspirin in primary prevention: sex and baseline risk matter
Lancet 2009;373:1821-1822 - Editoriale
Meta-analysis questions use of aspirin in primary prevention
Commento
tratto da Theheart.org
Aspirin for the prevention of cardiovascular events in patients with peripheral
artery disease: a meta-analysis of randomized trials
JAMA
2009;301:1909-19 - Abstract e diapositive
Aspirin and secondary prevention in peripheral artery disease: a perspective for
the early 21st century
JAMA
2009;301:1927-86 - Editoriale
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination
therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Lancet
2009 Jun 5 [Epub ahead of print] - Abstract e diapositive
Disponibile
su SEFAP abstract in italiano
Thiazolidinediones
and clinical outcomes in type 2 diabetes
Lancet 2009 Jun 5 [Epub ahead of print] - Editoriale
Avandia
on the RECORD: No "overall" CV risk increase, but trial remains controversial
Commento
tratto da Theheart.org
The effect
of statin alone or in combination with ezetimibe on postprandial lipoprotein composition
in obese metabolic syndrome patients
Atherosclerosis
2009;202:216-24 - Abstract e diapositive
Effects
of ezetimibe and simvastatin, coadministered and alone, on the in vivo kinetics
of APOB-48 and APOB-100 in men with mixed hyperlipidemia
J
Lipid Res 2009 Mar 22 [Epub] - Abstract e diapositive
Changes
in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or
simvastatin in men
J
Lipid Res 2009 Apr 20 [Epub] - Abstract e diapositive
Endothelial
progenitor cell levels in obese men with the metabolic syndrome and the effect
of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy
Eur
Heart J 2008;29:2808-17 - Abstract e diapositive
Ezetimibe
is an inhibitor of tumor angiogenesis
Am
J Pathol 2009;174:1017-26 - Abstract e diapositive
Ezetimibe,
and the combination of ezetimibe/simvastatin, and risk of cancer: A post-marketing
analysis
Journal
of Clinical Lipidology 2009;3:138-142 - Abstract e diapositive
Disponibili
su SEFAP abstract e tabella in italiano
Reduction
in C-reactive protein and LDL cholesterol and cardiovascular event rates after
initiation of rosuvastatin: A prospective study of the JUPITER trial
Lancet
2009;373:1175-82 - Abstract e diapositive
Bringing JUPITER down to earth
Lancet
2009;373:1147-48 - Editoriale
Lipid lowering for primary prevention
Lancet
2009;373:1152-55 - Editoriale
JUPITER: Low LDL and low CRP best for reducing events in primary prevention
Commento
tratto da Theheart.org
A randomized trial of rosuvastatin in the prevention of venous thromboembolism
N
Engl J Med 2009 [Epub] - Abstract e diapositive
JUPITER: Rosuvastatin reduces risk of VTE in healthy subjects
Commento
tratto da Theheart.org
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without
cardiovascular disease (TIPS): a phase II, double-blind, randomized trial
Lancet
2009 [Epub] - Abstract e diapositive
Can the polypill save the world from heart disease?
Lancet
2009;373:1313-14 - Editoriale
First
polypill data show promise; larger trials next step
Commento
tratto da Theheart.org
Combination
Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000
Participants from 42 Trials
Am
J Med 2009;122:290-300 - Abstract e diapositive
Combination antihypertensive therapy beats doubling monotherapy dose
Commento
tratto da MedWire New
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis
N
Engl J Med 2009;360:1395-407 - Abstract e diapositive
Sunset for Statins after AURORA?
N
Engl J Med 2009;360:1455-456 - Editoriale
Statins offer no cardiovascular protection for patients with end-stage renal disease
on hemodialysis
Commento
tratto da Theheart.org
EUROASPIRE
III: a survey on the lifestyle, risk factors and use of cardioprotective drug
therapies in coronary patients from 22 European countries
Eur
J Cardiovasc Prev Rehabil 2009 [Epub] - Abstract e diapositive
Disponibili
su SEFAP abstract e tabelle in italiano
Cardiovascular
prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and
III surveys in eight European countries
Lancet
2009;373:929-40 - Abstract e diapositive
Disponibili
su SEFAP abstract e tabelle in italiano
Secondary
cardiovascular risk prevention - we can do better
Lancet
2009;373:873-5 - Editoriale
Cardiologists
should be less passive about smoking cessation
Lancet
2009;373:867 - Editoriale
EUROASPIRE:
Better lifestyle management needed for patients with CHD
Commento
tratto da Theheart.org
Effect of
Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
N
Engl J Med 2009 [Epub] - Abstract e diapositive
ACTIVE-A:
Clopidogrel and aspirin reduce CV events in atrial fibrillation
Commento
tratto da Theheart.org
Aspirin
to prevent cardiovascular disease: the association of aspirin dose and clopidogrel
with thrombosis and bleeding
Ann
Intern Med 2009;150:379-86 - Abstract e diapositive
Aspirin
Use, Dose, and Clinical Outcomes in Postmenopausal Women With Stable Cardiovascular
Disease - The Women’s Health Initiative Observational Study
Circ
Cardiovasc Qual Outcomes 2009;2:78-87 - Abstract e diapositive
Aspirin
Therapy in Women - Back to the ABCs
Circ
Cardiovasc Qual Outcomes 2009;2:63-64 - Editoriale
Aspirin
for the prevention of cardiovascular disease: U.S. Preventive Services Task Force
Recommendation Statement
Ann
Intern Med 2009;150:396-404 - Abstract e diapositive
Aspirin
for Prevention and Treatment of Cardiovascular Disease
Ann
Intern Med 2009;150:414-416 - Editoriale
Aspirin:
More evidence that low dose is all that is needed
Commento
tratto da Theheart.org
Risk of
adverse outcomes associated with concomitant use of clopidogrel and proton pump
inhibitors following acute coronary syndrome
JAMA
2009;301:937-44 - Abstract e diapositive
More
data support adverse clopidogrel and proton-pump inhibitor interaction
Commento
tratto da Theheart.org
Platelet
reactivity after clopidogrel treatment assessed with point-of-care analysis and
early drug-eluting stent thrombosis
J
Am Coll Cardiol 2009;53:849-56 - Abstract e diapositive
Point-of-Care Platelet Function Analysis: Ready for Prime Time?
J Am
Coll Cardiol 2009;53:857-59 - Editoriale
More
support for clopidogrel platelet response testing
Commento
tratto da Theheart.org
Prasugrel
compared with clopidogrel in patients undergoing percutaneous coronary intervention
for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised
controlled trial
Lancet
2009;373:723-31 - Abstract e diapositive
Ischaemia
versus bleeding: the art of clinical decision-making
Lancet
2009;373:695-96 - Editoriale
Prasugrel
bests clopidogrel without bleeding risk in STEMI subgroup in TRITON-TIMI 38, researchers
say
Commento
tratto da Theheart.org
Prasugrel
approved in Europe
Commento
tratto da Theheart.org
Safety
and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous
coronary intervention: a randomised, double-blind, placebo-controlled phase II
study
Lancet
2009;373:919-28 - Abstract e diapositive
The ischaemia/bleeding
balance in PCI
Lancet
2009;373:872-73 - Editoriale
New
antiplatelet that may not up bleeding: Phase 2 results published
Commento
tratto da Theheart.org
Fine-particulate
air pollution and life expectancy in the United States
N
Engl J Med 2009;360:376-86 - Abstract e diapositive
Evaluating
the Effects of Ambient Air Pollution on Life Expectancy
N
Engl J Med 2009;360:413-15 - Editoriale
Particulate
air pollution, coronary heart disease and individual risk assessment: a general
overview
Eur
J Cardiovasc Prev Rehabil 2009 [Epub] - Abstract e diapositive
Cardiovascular
effects of air pollution
Clin
Sci 2008;115:175-87 - Abstract e diapositive
Ambient
air pollution exaggerates adipose inflammation and insulin resistance in a mouse
model of diet-induced obesity
Circulation
2009;119:538-46 - Abstract e diapositive
Could Dirty
Air Cause Diabetes?
Circulation
2009;119:492-94 - Editoriale
Psychological
distress as a risk factor for cardiovascular events: pathophysiological and behavioral
mechanisms
J
Am Coll Cardiol 2008;52:2156-62 - Abstract e diapositive
Psychological
Distress and Cardiovascular Risk: What Are the Links?
J
Am Coll Cardiol 2008;52:2163-65 - Editoriale
Genetic
determinants of response to clopidogrel and cardiovascular events
N
Engl J Med 2009;360:363-75 - Abstract e diapositive
Cytochrome
p-450 polymorphisms and response to clopidogrel
N
Engl J Med 2009;360:354-62 - Abstract e diapositive
Clopidogrel,
Genetics, and Drug Responsiveness
N
Engl J Med 2009;360:411-3 - Editoriale
Cytochrome
P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial
infarction: a cohort study
Lancet
2009;373:309-17 - Abstract e diapositive
Clopidogrel
in acute coronary syndrome: to genotype or not?
Lancet
2009;373:276-8 - Editoriale
A
population-based study of the drug interaction between proton pump inhibitors
and clopidogrel
CMAJ
2009 Jan 28 [Epub] - Abstract e diapositive
Increased
risk of reinfarction with clopidogrel and proton-pump inhibitors
Commento
tratto da Theheart.org
Glucose
Control and Vascular Complications in Veterans with Type 2 Diabetes
N
Engl J Med 2009;360:129-139 - Abstract e diapositive
VADT published: Intensive glucose
control fails to reduce cardiovascular events
Commento
tratto da Theheart.org
Intensive glycemic control and the prevention of cardiovascular
events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position
statement of ADA, ACC and AHA
Diabetes
Care 2009;32:187-927 - Abstract e diapositive
Use
of prescription and over-the-counter medications and dietary supplements among
older adults in the United States
JAMA
2008;300:2867-78 - Abstract e diapositive
One
in 25 US adults at risk for serious drug-drug interactions, mostly due to CV agents
Commento
tratto da Theheart.org
Update
of safety review-follow-up to the January 25, 2008 early communication about an
ongoing data review for ezetimibe/simvastatin
Update
of Safety Review - January 8, 2009
Effect
of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized
trial
JAMA
2008;300:2742-53 - Abstract e diapositive
Effect
of a Mediterranean diet supplemented with nuts on metabolic syndrome status: one-year
results of the PREDIMED randomized trial
Arch
Intern Med 2008;168:2449-58 - Abstract e diapositive
Dietary
patterns and the risk of acute myocardial infarction in 52 countries: results
of the INTERHEART study
Circulation
2008;118:1929-37 - Abstract e diapositive
Fish,
omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases
in a nationwide community-based cohort of Japanese men and women the JACC (Japan
Collaborative Cohort Study for Evaluation of Cancer Risk) Study
J
Am Coll Cardiol 2008;52:988-96 - Abstract e diapositive
Combined
impact of lifestyle factors on mortality: prospective cohort study in US women
BMJ
2008;337:a1440 - Abstract e diapositive
Adherence
to Mediterranean diet and health status: meta-analysis
BMJ
2008;337:a1344 - Abstract e diapositive
Adherence
to Mediterranean diet and risk of developing diabetes: prospective cohort study
BMJ
2008;336:1348-51 - Abstract e diapositive
Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis
in Type 2 Diabetes - The SANDS (Stop Atherosclerosis in Native Diabetics Study)
Trial
J
Am Coll Cardiol EPub - Abstract e diapositive
Long-Term
Effects of Fenofibrate on Carotid Intima-Media Thickness and Augmentation Index
in Subjects With Type 2 Diabetes Mellitus
J
Am Coll Cardiol EPub - Abstract e diapositive
Additional
Lipid Lowering Trials Using Surrogate Measurements of Atherosclerosis by Carotid
Intima-Media Thickness
More Clarity or Confusion?
J
Am Coll Cardiol EPub - Editoriale
Treating
diabetic patients to very low lipid targets regresses CIMT
Commento tratto da Theheart.org
Aggressive
Lipid Lowering Controls Atherosclerosis Effects
Commento
tratto da Medpagetoday
Cardiosource - ACC
- SANDS Trial Summary
Stop
Atherosclerosis in Native Diabetics Study (SANDS)
Cardiosource - ACC - FIELD Trial Summary
Fenofibrate
Intervention and Event Lowering in Diabetes (FIELD)
JUPITER
casts a large shadow: Moving from efficacy data to the big picture
Commento
tratto da Theheart.org
Normal
Cholesterol? You May Still Be At Risk
Commento
tratto da ACC-cardiosmart.org
Clinical
Trial Slide Sets from AHA 2008 - JUPITER
AHA
2008 Slidekit - Paul Ridker
Low-dose
aspirin for primary prevention of atherosclerotic events in patients with type
2 diabetes: a randomized controlled trial
JAMA
2008;300:2134-41 - Abstract e diapositive
Aspirin
for Primary Prevention of Cardiovascular Events in Diabetes - Still an Open Question
JAMA 2008;300:2180-2181 - Editoriale
JPAD:
No effect of aspirin primary-CV-event prevention in diabetics
Commento
tratto da Theheart.org
Type
2 diabetics studied in low-dose aspirin trial
American
Heart Association Scientific Session 2008
Clinical
Trial Slide Sets from AHA 2008 - JPAD
AHA
2008 Slidekit - Hisao Ogawa
JPAD
Trial Summary
Cardiosource
- ACC - Trial Summary
SEARCH
(Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine):
Randomized Comparison of Folic Acid 2 mg Plus Vitamin B12 1 mg Daily versus Placebo
for 7 Years in 12,064 Myocardial Infarction Survivors
American
Heart Association Scientific Session 2008 - Abstract
SEARCH
me: Null trial "morphed" into positive meta-analysis
Commento
tratto da Theheart.org
Study
finds folic acid not cardioprotective, though safe
American
Heart Association Scientific Session 2008
Clinical
Trial Slide Sets from AHA 2008 - SEARCH
AHA
2008 Slidekit -Rory Collins
SEARCH
Trial Summary
Cardiosource
- ACC - Trial Summary
Vitamins
E and C in the prevention of cardiovascular disease in men: the Physicians' Health
Study II randomized controlled trial
JAMA
2008;300:2123-33 - Abstract e diapositive
No
benefit of vitamin C or E for prevention of major cardiovascular events: Physicians'
Health Study II
Commento
tratto da Theheart.org
Two
antioxidant vitamins don’t protect against heart disease
American
Heart Association Scientific Session 2008
Vitamins
C and E Don't Cut Heart Risks - Study Shows Vitamins Don't Help Prevent Heart
Attacks and Strokes
Commento
tratto da ACC-cardiosmart.org
Physicians'
Health Study II Trial Summary
Cardiosource
- ACC - Trial Summary
Rosuvastatin to Prevent Vascular Events in Men and Women
with Elevated C-Reactive Protein
N
Engl J Med 2008;359:2195-207 - Abstract e diapositive
Expanding
the Orbit of Primary Prevention - Moving beyond JUPITER
N Engl J Med 2008;359:2280-82 - Editoriale
JUPITER hits New Orleans: Landmark study shows statins benefit healthy individuals
with high CRP levels
Commento
tratto da Theheart.org
Statin reduces heart
attack, stroke rates in patients with normal cholesterol but elevated C-reactive
protein
PM
Ridker: AHA Scientific Session 2008
American
Heart Association Comment on JUPITER trial
Rosuvastatin
Calcium Demonstrates
Dramatic CV Risk Reduction in a Large Statin Outcomes Study
Commento
tratto da PR Newswire
JUPITER
Trial Summary
Cardiosource
- ACC - Trial Summary
Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease
N
Engl J Med 2008;359:1897-1908 - Abstract e diapositive
Elevated
C-Reactive Protein in Atherosclerosis - Chicken or Egg?
N
Engl J Med 2008;359:1953-1955 - Editoriale
Stage-related
effect of statin treatment on the progression of aortic valve sclerosis and stenosi
Am
J Cardiol 2008;102:738-42 - Abstract e diapositive
Prognosis
and risk factors in patients with asymptomatic aortic stenosis and their modulation
by atorvastatin (20 mg)
Am
J Cardiol 2008;102:743-48 - Abstract e diapositive
Air
pollution and cardiovascular injury epidemiology, toxicology, and mechanisms
J
Am Coll Cardiol 2008;52:719-26 - Abstract e diapositive
Direct
cardiotoxicity from air pollution appreciated as possible hazard
Commento tratto da Theheart.org
Particulate
air pollution as a risk factor for ST-segment depression in patients with coronary
artery disease
Circulation
2008;118:1314-20 - Abstract e diapositive
Air
pollution is a risk factor for ST-segment depression in coronary patients
Commento
tratto da Theheart.org
Outcomes
of patients with acute coronary syndrome and previous coronary artery bypass
grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy
[PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)
Am
J Cardiol 2008;102:552-8 - Abstract e diapositive
Renin-angiotensin
blockade and kidney disease
Lancet 2008;372:511-512 - Editoriale
Renal
outcomes with telmisartan, ramipril, or both, in people at high vascular risk
(the ONTARGET study): a multicentre, randomised, double-blind, controlled trial
Lancet
2008;372:547-53 - Abstract e diapositive
BEAUTIFUL
results - the slower, the better?
Lancet
2008;372:779-780 - Editoriale
Ivabradine
for patients with stable coronary artery disease and left-ventricular systolic
dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
Lancet
2008;372:807-16 - Abstract e diapositive
Heart rate as a prognostic risk factor in patients with coronary artery disease
and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of
a randomised controlled trial
Lancet
2008;372:817-21 - Abstract e diapositive
Intensive
Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
N
Engl J Med 2008 [Epub ahead of print] - Abstract e diapositive
Analyses
of Cancer Data from Three Ezetimibe Trials
N
Engl J Med 2008 [Epub ahead of print] - Abstract e diapositive
Ezetimibe
and Cancer - An Uncertain Association
N
Engl J Med 2008 [Epub ahead of print] - Editoriale
Vytorin
rides out choppy SEAS
Theheart.org
- Commento
Intensive
Lipid-lowering Therapy with Simvastatin/Ezetimibe Combination Does not Affect
the Progression of Aortic Valve Stenosis: Results from the SEAS Study
American
Heart Association Today's Top Story
Simvastatin plus Ezetimibe in Aortic Stenosis - The SEAS study
AHA
- Clinical Trial Slide Sets from ESC Congress 2008 - TR Pedersen
Simvastatin and Ezetimibe in Aortic Stenosis (SEAS)
Trial Summary
Cardiosource
- ACC - Trial Summary
Statins,
Low-Density Lipoprotein Cholesterol, and Risk of Cancer
J
Am Coll Cardiol EPublication - 2008 - Abstract e diapositive
Low
LDL-C Levels and Cancer: Reassuring But Still Not Definitive
J
Am Coll Cardiol EPublication - 2008 - Editoriale
Statin
Treatment Does Not Cause Cancer
J
Am Coll Cardiol EPublication - 2008 - Editoriale
Independent
associations between low-density lipoprotein cholesterol and cancer among patients
with type 2 diabetes mellitus
CMAJ
2008;179(5):427-37 - Abstract e diapositive
Cancer
and cholesterol: understanding the V-shaped association in patients with diabetes
CMAJ
2008;179(5):403-4 - Editoriale
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart
failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled
trial
Lancet
2008 Aug 29 [Epub ahead of print] - Abstract e diapositive
Effect
of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial):
a randomised, double-blind, placebo-controlled trial
Lancet
2008 Aug 29 [Epub ahead of print] - Abstract e diapositive
Statins
and n-3 fatty acid supplementation in heart failure
Lancet
2008 Aug 29 [Epub ahead of print] - Editoriale
Omega-3
fatty acids, but not statin therapy, cuts mortality and hospitalizations in
heart failure
Theheart.org
- Commento
Fish
Oil Supplementation – But Not Statin Therapy – Reduces Death in Heart
Failure
American
Heart Association Today's Top Story
Effects of n-3 PUFA in patients with symptomatic chronic heart failure: the
GISSI-HF results
AHA
- Clinical Trial Slide Sets from ESC Congress 2008 - L. Tavazzi
Effects
of statins in patients with symptomatic chronic heart failure: the GISSI-HF
results
AHA
- Clinical Trial Slide Sets from ESC Congress 2008 - G. Tognoni
American
College of Cardiology: GISSI-HF: n-3 PUFA Study - Trial Summary
Cardiosource
- ACC - Trial Summary
American
College of Cardiology: GISSI-HF: Rosuvastatin Study - Trial Summary
Cardiosource
- ACC - Trial Summary
Beyond
Established and Novel Risk Factors Lifestyle Risk Factors for Cardiovascular
Disease
Circulation
2008;117;3031-3038- Abstract e diapositive
Ultrasound
imaging techniques for the evaluation of cardiovascular therapies
Eur
Heart J. 2008;29:849-58 - Abstract e diapositive
Lipids,
lipoproteins, and apolipoproteins as risk markers of myocardial infarction in
52 countries (the INTERHEART study): a case-control study
Lancet
2008; 372: 224–33 - Abstract e diapositive
Apolipoprotein
B/A1 and risk of cardiovascular disease
Lancet
2008;372:185-6 - Editoriale
Use
of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular
Causes
N
Engl J Med 2008;358:2107-16 - Abstract e diapositive
Multiple
biomarker panels for cardiovascular risk assessment
N
Engl J Med 2008;358:2172-4 - Editoriale
The
search for new cardiovascular biomarkers
Nature
2008;451:949-52 - Abstract e diapositive
New
cardiovascular risk determinants do exist and are clinically useful
Eur
Heart J 2008;29:436-40 - Abstract
New
cardiovascular risk factors exist, but are they clinically useful?
Eur
Heart J 2008;29:441-4 - Abstract
Acceleration of Cardiovascular Disease by a Dysfunctional Prostacyclin Receptor
Mutation - Potential Implications for Cyclooxygenase-2 Inhibition
Circ
Res 2008;102:986-93 - Abstract e diapositive
Improvements
in Long-Term Mortality After Myocardial Infarction and Increased Use of Cardiovascular
Drugs After Discharge - A 10-Year Trend Analysis
J
Am Coll Cardiol 2008;51:1247-54 - Abstract e diapositive
Treatment
of Hypertension in Patients 80 Years of Age or Older
N
Engl J Med 2008;358:1887-98 - Abstract e diapositive
SLCO1B1
Variants and Statin-Induced Myopathy - A Genomewide Study
N
Engl J Med 2008;359: [Epub] - Abstract e diapositive
The
role of statins in patients with arterial hypertension
Arch
Med Sci 2007; 3, 4A: S97-S101 - Abstract e diapositive
Role
of statin therapy in the management of patients with the metabolic syndrome
Arch
Med Sci 2007; 3, 4A: S102-S108 - Abstract e diapositive
The
role of statins in the prevention of stroke
Arch
Med Sci 2007; 3, 4A: S109-S114 - Abstract e diapositive
The
current role of statins in acute coronary syndrome
Arch
Med Sci 2007; 3, 4A: S115-S125 - Abstract e diapositive
The
SEAS Study
Commento
tratto da theheart.org
Simvastatin
and Ezetimibe in Aortic Stenosis (SEAS) Trial Summary
Cardiosource
- ACC - Trial Summary
Update
on the SEAS Study
Commento
tratto da PR Newswire
Results
From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study
Commento
tratto da PR Newswire
Independent
Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
Commento
tratto da PR Newswire
Reduction in blood pressure with statins: results from the UCSD Statin Study,
a randomized trial
Arch
Intern Med 2008;168:721-7 - Abstract e diapositive
'Real-life'
reduction in cholesterol with statins, 1993 to 2002
Br
J Clin Pharmacol 2008;65:587-92 - Abstract e diapositive
Lipids, apolipoproteins, and their ratios in relation
to cardiovascular events with statin treatment
Circulation
2008;117:3002-9 - Abstract e diapositive
Impact of preoperative statin therapy on adverse postoperative
outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000
patients.
Eur
Heart J 2008;29:1548-59 - Abstract e diapositive
Cholesterol lowering is more important than pleiotropic
effects of statins for endothelial function in patients with dysglycaemia and
coronary artery disease
Eur
Heart J 2008 [Epub ahead of print] - Abstract e diapositive
Metabolic syndrome and mortality in older adults: the Cardiovascular Health
Study
Arch
Intern Med 2008;168:969-78 - Abstract e diapositive
Overproduction
of very low-density lipoproteins is the hallmark of the dyslipidemia in the
metabolic syndrome
Arterioscler
Thromb Vasc Biol 2008;28:1225-36 - Abstract e diapositive
A changing paradigm for prevention of cardiovascular
disease: emergence of the metabolic syndrome as a multiplex risk factor
European
Heart Journal Supplements 2008;10:B16–B23 - Abstract e diapositive
Association between circulating oxidized low-density
lipoprotein and incidence of the metabolic syndrome
JAMA
2008;299:2287-93 - Abstract e diapositive
Can metabolic syndrome usefully predict cardiovascular
disease and diabetes? Outcome data from two prospective studies
Lancet
2008;371:1927-35 - Abstract e diapositive
Metabolic syndrome - what is the clinical usefulness?
Lancet
2008;371:1892-3 - Editoriale e diapositive
Diabetes
patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial
infarction carry the same cardiovascular risk: a population study of 3.3 million
people
Circulation
2008;117:1945-54 - Abstract e diapositive
Effects
of intensive glucose lowering in type 2 diabetes
N Engl
J Med 2008;358:2545-59 - Abstract e diapositive
Intensive blood glucose control and vascular outcomes
in patients with type 2 diabetes
N
Engl J Med 2008;358:2560-72 - Abstract e diapositive
Intensive Glycemic Control in the ACCORD and ADVANCE
Trials
N Engl
J Med 2007;358:2630-2633 - Editoriale
Glycemic Targets and Cardiovascular Disease
N Engl
J Med 2007;358:2633-2635 - Editoriale
Il
peso e i costi delle malattie croniche nei Paesi a basso e medio reddito
Lancet 2007;
370:1929-1938 - Abstract e diapositive
Aumento
degli interventi per la prevenzione delle malattie croniche: le evidenze
Lancet 2007;
370:1939-1946 - Abstract e diapositive
Prevenzione
delle malattie croniche: effetti sulla salute e costi finanziari delle strategie
per ridurre l'assunzione di sale e di controllo del tabacco
Lancet 2007;
370:2044-2053 - Abstract e diapositive
Prevenzione
delle malattie cardiovascolari in persone ad alto rischio nei Paesi a basso
e medio reddito: effetti sulla salute e costi
Lancet 2007;
370:2054-2062 - Abstract e diapositive
Prevenzione
delle malattie croniche: un invito ad agire
Lancet 2007;
370:2152-2157 - Abstract e diapositive
IDEAL:
ridurre i trigliceridi in pazienti con CHD stabile trattati con statine non
migliora la prognosi
IDEAL:
Lowering triglycerides in stable statin-treated CHD patients does not provide
benefit - Fonte: theheart.org
ADAGIO-LIPIDS:
la terapia con rimonabant riduce il grasso viscerale e migliora i parametri
lipidici plasmatici
ADAGIO-LIPIDS:
Rimonabant reduces visceral fat and improves lipid parameters - Fonte: theheart.org
La
terapia aggressiva con atorvastatina riduce le ricadute cardiovascolari in pazienti
con CKD
Intensive
atorvastatin effective in CKD patients and also reduces second and third cardiovascular
events - Fonte: theheart.org
SYNERGIE:
Un coretto stile di vita riduce la massa grassa e la sua distribuzione e migliora
i livelli dei fattori di rischio per la sindrome metabolica
SYNERGIE:
Lifestyle management reduces body fat distribution and metabolic-syndrome risk
factors - Fonte: theheart.org
PREDICT:
screening del calcio coronarico in pazienti diabetici per una migliore stratificazione
del rischio cardiovascolare?
PREDICT:
Calcium screening for diabetic patients to further stratify risk of cardiovascular
events?- Fonte: theheart.org
Simvastatin
with or without Ezetimibe in Familial Hypercholesterolemia
N
Engl J Med 2008;358:1431-1443 - Abstract e diapositive
Does ENHANCE Diminish Confidence
in Lowering LDL or in Ezetimibe?
N
Engl J Med 2007;358:1504-1507 - Editoriale
Cholesterol Lowering and Ezetimibe
N
Engl J Med 2007;358:1507-1508 - Editoriale
Use of Ezetimibe in the United
States and Canada
N
Engl J Med 2008;358: [Epub Mar 30] - Abstract e diapositive
ENHANCE published, presented, discussed,
and debated: Experts mull over what the findings mean
Theheart.org
- Commento
Medical News: ACC: ENHANCE Data
on Ezetimibe/Simvastatin (Vytorin) Reveal Wavy Bottom Line
MedPage
Today - Commento
American College of Cardiology:
ENHANCE Trial Summary
Cardiosource
- ACC - Trial Summary
Effect
of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary
Angiography. A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived
Coronary Atheroma Burden
Circulation
2008 Mar 31 [Epub ahead of print] - Abstract e diapositive
ASTEROID:
A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived
Coronary Atheroma Burden
American
Heart Association Today's Top Story
Effect
of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary
Angiography in ASTEROID
AHA
- Clinical Trial Slide Sets from ACC 2008 - M. Ballantyne
Crestor
Outcomes Study JUPITER Closes Early Due To Unequivocal Evidence Of Benefit
Comunicato
stampa AstraZeneca
JUPITER halted: Rosuvastatin significantly
reduces cardiovascular morbidity and mortality
Theheart.org
- Commento
Telmisartan,
Ramipril, or Both in Patients at High Risk for Vascular Events
N
Engl J Med 2008 [Epub ahead of print Mar 31] - Abstract e diapositive
ACE Inhibitors in Cardiovascular
Disease - Unbeatable?
N
Engl J Med 2008 [Epub ahead of print Mar 31] - Editoriale
ONTARGET: Telmisartan shows similar
benefit to ramipril in high-risk vascular disease/diabetes patients
Theheart.org
- Commento
American College of Cardiology:
ON TARGET Trial Summary
Cardiosource
- ACC - Trial Summary
Results of the ONTARGET Study Comparing
Ramipril With Telmisartan, and Its Combination in High-Risk Individuals Without
Heart Failure
AHA
- Clinical Trial Slide Sets from ACC 2008 - S. Yusuf
Comparison
of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients
with type 2 diabetes: the PERISCOPE randomized controlled trial
JAMA
2008;299:1561-73 - Abstract e diapositive
Does
PERISCOPE Provide a New Perspective on Diabetic Treatment?
JAMA
2008;299:1603-1604 - Editoriale
PERISCOPE:
Pioglitazone prevents atherosclerosis progression in diabetics
Theheart.org
- Commento
American
College of Cardiology: PERISCOPE Trial Summary
Cardiosource
- ACC - Trial Summary
Comparison
of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients
With Type 2 Diabetes: The PERISCOPE Randomized Controlled Trial
AHA
- Clinical Trial Slide Sets from ACC 2008 - S.E. Nissen
Effect of rimonabant on progression
of atherosclerosis in patients with abdominal obesity and coronary artery disease:
the STRADIVARIUS randomized controlled trial
JAMA
2008;299:1547-60 - Abstract e diapositive
The
Hope and Fear of Rimonabant
JAMA
2008;299:1601-1602 - Editoriale
Out
of tune: Rimonabant fails to slow progression of CAD in STRADIVARIUS
Theheart.org
- Commento
STRADIVARIUS
Yields Mixed Results on Rimonabant
American
Heart Association Today's Top Story
American
College of Cardiology: STRADIVARIUS Trial
Cardiosource
- ACC - Trial Summary
Cardiovascular
Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials. The Cross Trial Safety
Analysis
Circulation
2008 [Epub ahead of print Mar 31] - Abstract e diapositive
New
data will help guide prescribing of celecoxib
Theheart.org
- Commento
Cardiovascular
Risk of Celecoxib in Six Randomized Placebo-controlled Trials:The Cross Trial
Safety Analysis
AHA
- Clinical Trial Slide Sets from ACC 2008 - S.D. Solomon
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
N
Engl J Med; Epub March 30, 2008 - Abstract
Polymorphisms associated with cholesterol and risk of cardiovascular events
N
Engl J Med 2008;358:1240-9 - Abstract e diapositive
The metabolic syndrome predicts cardiovascular events in subjects with normal
fasting glucose: results of a 15 years follow-up in a Mediterranean population
Atherosclerosis
2008;197:147-53 - Abstract e diapositive
Metabolic syndrome components in african-americans and european-american patients
and its relation to coronary artery disease
Am
J Cardiol 2007;100:830-4 - Abstract e diapositive
Ten-year
cardiovascular disease risk of metabolic syndrome without central obesity in middle-aged
chinese
Am
J Cardiol 2007;100:835-9 - Abstract e diapositive
Clinical
utility of different lipid measures for prediction of coronary heart disease in
men and women
JAMA
2007;298:776-85 - Abstract e diapositive
Metabolic
syndrome and risk of development of atrial fibrillation: the Niigata preventive
medicine study
Circulation
2008;117:1255-60 - Abstract e diapositive
Effects of statins in patients with chronic kidney disease: meta-analysis and
meta-regression of randomised controlled trials
BMJ
2008 Feb 25 [Epub ahead of print] - Abstract e diapositive
Multimarker
approach to evaluate the incidence of the metabolic syndrome and longitudinal
changes in metabolic risk factors: the Framingham Offspring Study
Circulation
2007;116:984-92 - Abstract e diapositive
The
metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study
in elderly non-diabetic Finns
Eur
Heart J 2007;28:857-64 - Abstract e diapositive
The
metabolic syndrome predicts incident stroke. A 14-year follow-up study in elderly
people in Finland
Stroke
2008;39:1078-83 - Abstract e diapositive
Metabolic
syndrome and risk of incident cardiovascular events and death: a systematic review
and meta-analysis of longitudinal studies
J
Am Coll Cardiol 2007;49:403-14 - Abstract e diapositive
Association
between copayment and adherence to statin treatment initiated after coronary heart
disease hospitalization: A longitudinal, retrospective, cohort study
Clin
Ther 2007;29:2748-57 - Abstract e diapositive
Adherence
to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological
study in Italy
Eur
J Clin Pharmacol 2008 Jan 5 [Epub ahead of print] - Abstract e diapositive
Discontinuation
of lipid modifying drugs among commercially insured United States patients in
recent clinical practice
Am
J Cardiol 2007;99:530-4 - Abstract e diapositive
Comparison
of utilization of statin therapy at hospital discharge and six-month outcomes
in patients with an acute coronary syndrome and serum low-density lipoprotein>or=100
mg/dl versus<100 mg/dl
Am
J Cardiol 2007;100:913-8 - Abstract e diapositive
Adherence
to evidence-based statin guidelines reduces the risk of hospitalizations for acute
myocardial infarction by 40%: a cohort study
Eur
Heart J 2007;28:154-9 - Abstract e diapositive
Interventions
to enhance medication adherence in chronic medical conditions: a systematic review
Arch
Intern Med 2007;167:540-50 - Abstract e diapositive
Discontinuation
of statin therapy and clinical outcome after ischemic stroke
Stroke
2007;38:2652-7 - Abstract e diapositive
Do
We Need to Assess the Effect of Treatment Withdrawal?
The Paradigm of Life-Long Prevention
Stroke
2007;38:2629-2630 - Commento editoriale
Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia
therapy: the CHECK-UP study: a randomized controlled trial
Arch
Intern Med 2007;167:2296-303 - Abstract e diapositive
Salute:
Mappa Europea Rischio Infarto e Ictus, bene l'Italia
Ansa
- Mar 5 Feb
An update on regional variation in cardiovascular mortality within Europe
Eur
Heart J. 2008 Feb 6 [Epub ahead of print] - Abstract e diapositive
Changing
pattern of CVD mortality in Europe
Commento
tratto da theheart.org
Tramonta
il mito del colesterolo (cattivo)
Adriana
Bazzi - Corriere della Sera 07 febbraio 2008
Il
colesterolo (cattivo): farmaci e dubbi
Lettera
di risposta di Rodolfo Paoletti e Andrea Peracino - Corriere della Sera 12 febbraio
2008
Studi sulla riduzione del colesterolo
Lettera
di risposta di Andrea Poli e Alberico L. Catapano - Corriere della Sera 14 febbraio
2008
Statins
offer no protection against Alzheimer's disease
Commento
tratto da theheart.org
FDA
approves combination niacin and simvastatin
Commento
tratto da theheart.org
Abbott
Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination
Medicine for Comprehensive Cholesterol Management
Commento
tratto da PR Newswire
For Safety, NHLBI Changes Intensive Blood Sugar Treatment Strategy in Clinical
Trial of Diabetes and Cardiovascular Disease
NHLBI
- Press Release and Resources
Intensive-glycemic-control
arm of ACCORD stopped
Commento
tratto da theheart.org
Statement
from the American Diabetes Association Related to ACCORD Trial Announcement
Commento
tratto da PR Newswire
ACCORD
intensive glucose-lowering arm stopped
Commento
tratto da Incirculation.net
The
day after: Experts puzzled over increased death rate in ACCORD
Commento
tratto da theheart.org
Beneficial effects of aggressive LDL cholesterol lowering in women with stable
coronary heart disease in the Treating to New Targets (TNT) study
Heart
2007 Dec 10 [Epub ahead of print] - Abstract e diapositive
Usefulness
of pravastatin in primary prevention of cardiovascular events in women: analysis
of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult
Japanese (MEGA study)
Circulation
2008;117:494-502 - Abstract e diapositive
Rate
of progression of coronary atherosclerotic plaque in women
J
Am Coll Cardiol 2007;49:1546-51 - Abstract e diapositive
A
meta-analysis of 94,492 patients with hypertension treated with beta blockers
to determine the risk of new-onset diabetes mellitus
Am
J Cardiol 2007;100:1254-62 - Abstract e diapositive
Serum
cystatin C predicts progression of subclinical coronary atherosclerosis in individuals
with type 1 diabetes
Diabetes
2007;56:2774-9 - Abstract e diapositive
Prevalence
of nonalcoholic fatty liver disease and its association with cardiovascular disease
among type 2 diabetic patients
Diabetes
Care 2007;30:1212-8 - Abstract e diapositive
Incidence
of coronary heart disease in type 2 diabetic men and women: impact of microvascular
complications, treatment, and geographic location
Diabetes
Care 2007;30:1241-7 - Abstract e diapositive
Significance
of endothelial progenitor cells in subjects with diabetes
Diabetes
Care 2007;30:1305-13 - Abstract e diapositive
Insulin
resistance, the metabolic syndrome, and risk of incident cardiovascular disease:
a population-based study
J
Am Coll Cardiol 2007;49:2112-9 - Abstract e diapositive
Efficacy
of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised
trials of statins: a meta-analysis
Lancet
2008;371:117-25 - Abstract e diapositive
Effect
of Combination Ezetimibe and High-Dose Simvastatin Alone on the Atherosclerotic
Process in Subjects with Heterozygous Familial Hypercholesterolemia (ENHANCE)
trial
Comunicato
stampa
ENHANCE results yield disappointment for ezetimibe
Fonte: theheart.org
Commento
- Diapositive
Expression
of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol
transport
Circulation
2007;116:1267-73 - Abstract e diapositive
Punto
di Vista Clinico
Circulation
2007;116:1267-73 - Punto di Vista Clinico
Torcetrapib
and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 Study):
a randomised, double-blind trial
Lancet
2007;370:153-60 - Abstract e diapositive
HDL
cholesterol and atherosclerosis
Lancet
2007;370:107-8 - Editoriale
Indices
of reverse cholesterol transport in subjects with metabolic syndrome after treatment
with rosuvastatin
Atherosclerosis
2007- Epub ahead of print - Abstract e diapositive
Fenofibrate
increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression
Journal
of Lipid Research 2007;48:1763-1771 - Abstract e diapositive
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins
in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy
individuals: two double-blind, randomised placebo-controlled phase I studies
Lancet
2007;370:1907-14 - Abstract e diapositive
CETP
inhibition
Lancet
2007;370:1882-83 - Editoriale
The
CETP TaqIB polymorphism is associated with the risk of sudden death in type2 diabetic
patients
Diabetes
Care 2007;30:2863-7 - Abstract e diapositive
High
serum cholesteryl ester transfer rates and small high-density lipoproteins are
associated with young age in patients with acute myocardial infarction
J
Am Coll Cardiol 2007;50:1948-55 - Abstract e diapositive
Is
the cholesteryl ester transfer protein proatherogenic or antiatherogenic in humans?
J
Am Coll Cardiol 2007;50:1956-8 - Editoriale
Ischemic heart disease events triggered by short-term exposure to fine particulate
air pollution
Circulation
2006;114:2443-8 - Abstract e diapositive
When
a myocardial infarction comes out of the not-so-blue air
Circulation
2006;114:2430-1 - Editoriale
Long-term
exposure to air pollution and incidence of cardiovascular events in women
N
Engl J Med 2007;356:447-58 - Abstract e diapositive
Cardiovascular
risks from fine particulate air pollution
N
Engl J Med 2007;356:511-3 - Editoriale
Ischemic
and thrombotic effects of dilute diesel-exhaust inhalation in men with coronary
heart disease
N
Engl J Med 2007;357:1075-82 - Abstract e diapositive
Air
pollution, exercise, and cardiovascular risk
N
Engl J Med 2007;357:1147-9 - Editoriale
Effects of Torcetrapib in Patients at High Risk for Coronary Events
N
Engl J Med 2007;357:2109-22 - Abstract e diapositive
Illuminating
HDL - Is It Still a Viable Therapeutic Target?
N
Engl J Med 2007;357:2180-3 - Editoriale e diapositive
New
torcetrapib data rejuvenate interest in other CETP inhibitors
Fonte:
theheart.org - Sue Hughes - 5 Novembre 2007
Rosuvastatin
in Older Patients with Systolic Heart Failure
N
Engl J Med 2007 Nov 5; [Epub ahead of print] - Abstract e diapositive
Statins
for Ischemic Systolic Heart Failure
N
Engl J Med 2007 Nov 5; [Epub ahead of print] - Editoriale
CORONA:
Little clinical benefit seen in first major statin trial in heart failure
Fonte:
theheart.org - Steve Stiles - 5 Novembre 2007
Association
of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular
events: a systematic review and meta-analysis
Arch
Intern Med 2007;167:1593-9 - Abstract e diapositive
Warfarin
versus aspirin for stroke prevention in an elderly community population with atrial
fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study,
BAFTA): a randomised controlled trial
Lancet
2007;370:493-503 - Abstract e diapositive
HDL
cholesterol, very low levels of LDL cholesterol, and cardiovascular events
N
Engl J Med 2007;357:1301-10 - Abstract e diapositive
Long-term
follow-up of the West of Scotland Coronary Prevention Study
N
Engl J Med 2007;357:1477-86 - Abstract e diapositive
Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility
analysis
Arch
Intern Med 2007;167:290-5 - Abstract e diapositive
Adherence
to statin therapy under drug cost sharing in patients with and without acute myocardial
infarction: a population-based natural experiment
Circulation
2007;115:2128-35 - Abstract e diapositive
Evaluation
of the cost savings and clinical outcomes of switching patients from atorvastatin
to simvastatin and losartan to candesartan in a Primary Care setting
Int
J Clin Pract 2007;61:15-23 - Abstract e diapositive
Physician
awareness of drug cost: a systematic review
PLoS
Med 2007;4:e283 - Abstract e diapositive
ASSET
(Age/Sex Standardised Estimates of Treatment): a research model to improve the
governance of prescribing funds in Italy
PLoS
ONE 2007;2:e592 - Abstract e diapositive
Statin
use in patients with extremely low low-density lipoprotein levels is associated
with improved survival
Circulation
2007;116:613-8 - Abstract e diapositive
Statin
treatment in children with familial hypercholesterolemia: the younger, the better
Circulation
2007;116:664-8 - Abstract e diapositive
Nonfasting
triglycerides and risk of myocardial infarction, ischemic heart disease, and death
in men and women
JAMA
2007;298:299-308 - Abstract e diapositive
Fasting
compared with nonfasting triglycerides and risk of cardiovascular events in women
JAMA
2007;298:309-16 - Abstract e diapositive
Effect
of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis,
and cancer: insights from large randomized statin trials
J
Am Coll Cardiol 2007;50:409- - Abstract e diapositive
The safety of statins in clinical practice
Lancet
2007;370:[Epub ahead of print] - Abstract e diapositive
Factors
Associated with Findings of Published Trials of Drug-Drug Comparisons: Why Some
Statins Appear More Efficacious than Others
PLoS
Med 2007;4:e184 - Abstract e diapositive
Statins
and the risk of lung, breast, and colorectal cancer in the elderly
Circulation
2007;115:27-33 - Abstract e diapositive
Effect
of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis
of the Treating to New Targets (TNT) study
Circulation
2007;115:576-83 - Abstract e diapositive
Effects
of intensive versus moderate lipid-lowering therapy on myocardial ischemia in
older patients with coronary heart disease: results of the Study Assessing Goals
in the Elderly (SAGE)
Circulation
2007;115:700-7 - Abstract e diapositive
C-reactive
protein and prediction of coronary heart disease and global vascular events in
the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
Circulation
2007;115:981-9 - Abstract e diapositive
Atorvastatin
pretreatment improves outcomes in patients with acute coronary syndromes undergoing
early percutaneous coronary intervention: results of the ARMYDA-ACS randomized
trial
J
Am Coll Cardiol 2007;49:1272-8 - Abstract e diapositive
Risk factors for coronary artery disease in patients with elevated high-density
lipoprotein cholesterol
Am
J Cardiol 2007;99:1-4 - Abstract e diapositive
Usefulness
of a complete blood count-derived risk score to predict incident mortality in
patients with suspected cardiovascular disease
Am
J Cardiol 2007;99:169-74 - Abstract e diapositive
N-terminal
Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction
among 20,536 patients in the MRC/BHF heart protection study
J
Am Coll Cardiol 2007;49:311-9 - Abstract e diapositive
Can
Biomarkers Identify Women at Increased Stroke Risk? The Women's Health Initiative
Hormone Trials
PLoS
Clin Trials 2007;2:e28 - Abstract e diapositive
Prognostic
significance of the Centers for Disease Control/American Heart Association high-sensitivity
C-reactive protein cut points for cardiovascular and other outcomes in patients
with stable coronary artery disease
Circulation
2007;115:1528-36 - Abstract e diapositive
Receiver-operating
characteristic analysis for evaluating diagnostic tests and predictive models
Circulation
2007;115:654-7 - Abstract e diapositive
Use
and misuse of the receiver operating characteristic curve in risk prediction
Circulation
2007;115:928-35 - Abstract e diapositive
Comparison
of interleukin-6 and C-reactive protein for the risk of developing hypertension
in women
Hypertension
2007;49:304-10 - Abstract e diapositive
Multiple
biomarkers for the prediction of first major cardiovascular events and death
N
Engl J Med 2006;355:2631-9 - Abstract e diapositive
Biomarkers
for prediction of cardiovascular events - Comments
and author reply
N
Engl J Med 2007;356:1473; author reply 1474-5
Non-high-density lipoprotein and very-low-density lipoprotein cholesterol
and their risk predictive values in coronary heart disease
Am
J Cardiol 2006;98:1363-8 - Abstract e diapositive
Comparison
of mortality rates in statin users versus nonstatin users in a United States
veteran population
Am
J Cardiol 2006;98:923-8 - Abstract e diapositive
Triglycerides
and the risk of coronary heart disease: 10,158 incident cases among 262,525
participants in 29 Western prospective studies
Circulation
2007;115:450-8 - Abstract e diapositive
Statin
use and hospitalization for sepsis in patients with chronic kidney disease
JAMA
2007;297:1455-64 - Abstract e diapositive
Valsartan in a Japanese population with hypertension and other cardiovascular
disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality
study
Lancet
2007;369:1431-9 - Abstract e diapositive
The
genetic dissection of essential hypertension
Nat
Rev Genet 2006;7:829-40 - Abstract e diapositive
Once-yearly
zoledronic acid for treatment of postmenopausal osteoporosis
N
Engl J Med 2007;356:1809-22 - Abstract e diapositive
Treatment
of periodontitis and endothelial function
N
Engl J Med 2007;356:911-20 - Abstract e diapositive
Rosiglitazone Evaluated for Cardiovascular Outcomes - An Interim Analysis
N
Engl J Med. 2007 Jun 5; [Epub ahead of print] - Abstract e diapositive
Rosiglitazone
- Continued Uncertainty about Safety
N
Engl J Med. 2007 Jun 5; [Epub ahead of print] - Editoriale
Rosiglitazone
and Cardiotoxicity - Weighing the Evidence
N
Engl J Med. 2007 Jun 5; [Epub ahead of print] - Editoriale
The
Record on Rosiglitazone and the Risk of Myocardial Infarction
N
Engl J Med. 2007 Jun 5; [Epub ahead of print] - Editoriale
Cardiovascular
safety of rosiglitazone
Lancet
2007; 369:1995-1996 - Editoriale e diapositive
Rosiglitazone:
seeking a balanced perspective
Lancet
2007; 369:1834 - Editoriale
Rosiglitazone
RECORD study: glucose control outcomes at 18 months
Diabet
Med 2007;24:626-34 - Abstract e diapositive
Rosiglitazone
and implications for pharmacovigilance
BMJ.2007;
334: 1233-1234 - Editoriale
ROSIGLITAZONE
E RISCHIO DI INFARTO DEL MIOCARDIO
Fonte SEFAP (Rassegna
di lavori tradotti)
Notizie in breve su Rosiglitazone
Potent reduction of apolipoprotein B and low-density
lipoprotein cholesterol by short-term administration of an antisense inhibitor
of apolipoprotein
Circulation
2006;114:1729-35 - Abstract e diapositive
Incremental
benefit and cost-effectiveness of high-dose statin therapy in high-risk patients
with coronary artery disease
Circulation
2007;115:2398-409 - Abstract e diapositive
Do
statins reduce blood pressure?: a meta-analysis of randomized, controlled trials
Hypertension
2007;49:792-8 - Abstract e diapositive
Rosuvastatin
affecting aortic valve endothelium to slow the progression of aortic stenosis
J
Am Coll Cardiol 2007;49:554- - Abstract e diapositive
Physician follow-up and provider continuity are associated with long-term medication
adherence: a study of the dynamics of statin use
Arch
Intern Med 2007;167:847-52 - Abstract e diapositive
Comparison
of intravascular ultrasound and quantitative coronary angiography for the assessment
of coronary artery disease progression
Circulation
2007;115:1851-7 - Abstract e diapositive
A
direct comparison of intravascular ultrasound and quantitative coronary arteriography:
implications for measures of atherosclerosis as clinical surrogates
Circulation
2007;115:1824-6 - Abstract e diapositive
Adherence
to statin therapy under drug cost sharing in patients with and without acute myocardial
infarction: a population-based natural experiment
Circulation
2007;115:2128-35 - Abstract e diapositive
Telomere
length of circulating leukocytes is decreased in patients with chronic heart failure
J
Am Coll Cardiol 2007;49:1459-64 - Abstract e diapositive
Receptor
feasts on sugar and cholesterol
Nat
Med 2007;13:128-9 - Abstract e diapositive
Brain
glucose metabolism controls the hepatic secretion of triglyceride-rich lipoproteins
Nat
Med 2007;13:171-80 - Abstract e diapositive
Effect
of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular
Causes
N
Engl J Med. 2007; [Epub ahead of print] - Abstract e diapositive
Rosiglitazone
and Cardiovascular Risk
N
Engl J Med. 2007; [Epub ahead of print] - Editoriale
Altri commenti alla pubblicazione nella sezione "Notizie
in breve"
The
effect of weight loss on C-reactive protein: a systematic review
Arch
Intern Med 2007;167:31-9 - Abstract e diapositive
ABC
of obesity - Strategies for preventing obesity
BMJ 2006;333:959-62 - Abstract e diapositive
Pharmacological
and lifestyle interventions to prevent or delay type 2 diabetes in people with
impaired glucose tolerance: systematic review and meta-analysis
BMJ 2007;334:299 - Abstract e diapositive
Efficacy
and tolerability of rimonabant in overweight or obese patients with type 2 diabetes:
a randomised controlled study
Lancet 2006;368:1660-72 - Abstract e diapositive
An
obesity-associated gut microbiome with increased capacity for energy harvest
Nature 2006;444:1027-31 - Abstract e diapositive
Physiology:
obesity and gut flora
Nature 2006;444:1009-10 - Abstract
Microbial ecology: human gut microbes associated with obesity
Nature 2006;444:1022-3 - Abstract
Effect of rosuvastatin on progression of carotid intima-media thickness in
low-risk individuals with subclinical atherosclerosis: the METEOR Trial
JAMA
2007;297:1344-53 - Abstract e diapositive
Effects
of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia
or hypercholesterolemia: two randomized controlled trials
JAMA 2007;297:1362-73 - Abstract e diapositive
Effects
of Reconstituted High-Density Lipoprotein Infusions on Coronary Atherosclerosis:
A Randomized Controlled Trial
JAMA 2007;297: [Epub ahead of print] - Abstract e diapositive
Effect
of Torcetrapib on the progression of coronary atherosclerosis
N Engl J Med 2007;356:1304-16 - Abstract e diapositive
Effect
of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia
N Engl J Med 2007;356: [Epub ahead of print] - Abstract e diapositive
Vitamin
B6, B12, and folic acid supplementation and cognitive function: a systematic
review of randomized trials
Arch
Intern Med 2007;167:21-30 - Abstract e diapositive
Effect
of raw garlic vs commercial garlic supplements on plasma lipid concentrations
in adults with moderate hypercholesterolemia: a randomized clinical trial
Arch Intern Med 2007;167:346-53 - Abstract e diapositive
Mortality
in randomized trials of antioxidant supplements for primary and secondary prevention:
systematic review and meta-analysis
JAMA 2007;297:842-57 - Abstract e diapositive
Effect
of 3-year folic acid supplementation on cognitive function in older adults in
the FACIT trial: a randomised, double blind, controlled trial
Lancet 2007;369:208-16 - Abstract e diapositive
Biomarkers
of cardiovascular disease: molecular basis and practical considerations
Circulation
2006;113:2335-62 - Abstract e diapositive
Determinants
of arterial wall remodeling during lipid-lowering therapy: serial intravascular
ultrasound observations from the Reversal of Atherosclerosis with Aggressive
Lipid Lowering Therapy (REVERSAL) trial
Circulation 2006;113:2826-34 - Abstract e diapositive
Respiratory
symptoms, pulmonary function, and markers of inflammation among bar workers
before and after a legislative ban on smoking in public places
JAMA 2006;296:1742-8 - Abstract e diapositive
N-terminal
fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular
events, and mortality in patients with stable coronary heart disease
JAMA 2007;297:169-76 - Abstract e diapositive
Stop Hypertension with the Acupuncture Research Program (SHARP): results of
a randomized, controlled clinical trial
Hypertension
2006;48:838-45 - Abstract e diapositive
Incident
diabetes in clinical trials of antihypertensive drugs: a network meta-analysis
Lancet
2007;369:201-7 - Abstract e diapositive
Carotid
intima-media thickness and antihypertensive treatment: a meta-analysis of randomized
controlled trials
Stroke 2006;37:1933-40 - Abstract e diapositive
The effect of early, intensive statin therapy on acute coronary syndrome: a
meta-analysis of randomized controlled trials
Arch
Intern Med 2006;166:1814-21 - Abstract e diapositive
Risks
associated with statin therapy: a systematic overview of randomized clinical
trials
Circulation 2006;114:2788-9 - Abstract e diapositive
Effects
of statin therapy on arrhythmic events and survival in patients with nonischemic
dilated cardiomyopathy
J Am Coll Cardiol 2006;48:1228-33 - Abstract e diapositive
Statin
use and incident nuclear cataract
JAMA 2006;295:2752-8 - Abstract e diapositive
ABC
of obesity. Risk factors for diabetes and coronary heart disease
BMJ
2006;333:1009-11 - Diapositive
Prospective
study of diabetes and risk of hip fracture: the Nurses' Health Study
Diabetes
Care 2006;29:1573-8 - Abstract e diapositive
A
strong dose-response relation between serum concentrations of persistent organic
pollutants and diabetes: results from the National Health and Examination Survey
1999-2002
Diabetes
Care 2006;29:1638-44 - Abstract e diapositive
Glycemic
durability of rosiglitazone, metformin, or glyburide monotherapy
N
Engl J Med 2006;355:2427-43 - Abstract e diapositive
Apolipoprotein-B, low-density lipoprotein cholesterol,
and the long-term risk of coronary heart disease in men
Am
J Cardiol 2006;97:997-1001 - Abstract e diapositive
Biomarkers in acute cardiac disease:
the present and the future
J Am Coll Cardiol 2006;48:1-110 - Abstract e diapositive
The apoB/apoA-I ratio: a strong,
new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a
review of the evidence
J
Intern Med 2006;259:493-519 - Abstract e diapositive
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups
derived from a randomised trial of 20536 people
BMJ
2006;333:1145 - Abstract e diapositive
Strength of evidence for perioperative use of statins to reduce cardiovascular
risk: systematic review of controlled studies
BMJ; 2006;332:1149-11520 - Abstract e diapositive
Statins
and outcomes in patients admitted to hospital with community acquired pneumonia:
population based prospective cohort study
BMJ; 2006;333:999-1003 - Abstract e diapositive
Effect
of low-density lipoprotein cholesterol on angiotensin II sensitivity: a randomized
trial with fluvastatin
Hypertension 2006;47:1125-30 - Abstract e diapositive
Statin
therapy and risks for death and hospitalization in chronic heart failure
JAMA 2006;296:2105-11 - Abstract e diapositive
ATP-Binding cassette cholesterol transporters and cardiovascular disease
Circ
Res 2006;99:1031-43 - Abstract e diapositive
Reduction
of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors,
and angiotensin receptor blockers in patients with chronic obstructive pulmonary
disease
J Am Coll Cardiol. 2006;47:2554-60 - Abstract e diapositive
Angiotensin-converting
enzyme inhibitors and aortic rupture: a population-based case-control study
Lancet 2006;368:659-65 - Abstract e diapositive
Cardiovascular
disease prevention with a multidrug regimen in the developing world: a cost-effectiveness
analysis
Lancet 2006;368:679-86 - Abstract e diapositive
Sospesa
la sperimentazione clinica con Torcetrapib
Comunicato
stampa Pfizer
Commento
a cura di AL Catapano e A Poli
AL Catapano
- Adnkronos Salute
Over-The-Counter
Statins Are Worth Considering in Primary Prevention of Cardiovascular Disease
Circ 2006;114:1310-1314 - Editoriale
The
Argument Against the Appropriateness of Over-the-Counter Statins
Circ 2006;114:1315-1320 - Editoriale e Diapositive
Effect
of lowering LDL cholesterol substantially below currently recommended levels in
patients with coronary heart disease and diabetes: the Treating to New Targets
(TNT) study
Diabetes Care 2006;29:1220-6 - Abstract e diapositive
Reduction
of low-density lipoprotein cholesterol in patients with coronary heart disease
and metabolic syndrome: analysis of the Treating to New Targets study
Lancet 2006;368:919-28 - Abstract e diapositive
Statin
treatment is not associated with consistent alterations in inflammatory status
of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing
carotid endarterectomy
Stroke 2006;37:2054-60 - Abstract e diapositive
Adverse
effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis
of randomized trials
JAMA
2006;296:1619-32 - Abstract e diapositive
Cardiovascular
risk and inhibition of cyclooxygenase: a systematic review of the observational
studies of selective and nonselective inhibitors of cyclooxygenase 2
JAMA
2006;296:1633-44 - Abstract e diapositive
Celecoxib
for the prevention of sporadic colorectal adenomas
N
Engl J Med 2006;355:873-84 - Abstract e diapositive
Celecoxib
for the prevention of colorectal adenomatous polyps
N Engl J Med 2006;355:885-95 - Abstract e diapositive
Intracoronary Injection of Mononuclear Bone Marrow Cells in Acute Myocardial Infarction
New
Engl J Med 2006; 355:1199-209 - Abstract e diapositive
Intracoronary
Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction
New
Engl J Med 2006; 355:1210-21 - Abstract e diapositive
Transcoronary
Transplantation of Progenitor Cells after Myocardial Infarction
New
Engl J Med 2006; 355:1122-32 - Abstract e diapositive
Primary
prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a
prospective randomised controlled trial
Lancet
2006;368:1155-63 - Abstract e diapositive
The
value of medical spending in the United States, 1960-2000
N Engl J Med 2006;355:920-7 - Abstract e diapositive
Angiotensin-converting-enzyme inhibitors in stable vascular disease
without left ventricular systolic dysfunction or heart failure: a combined analysis
of three trials
Lancet 2006; 368: 581 - Abstract e diapositive
Tobacco use and risk of myocardial infarction in
52 countries in the INTERHEART study: a case-control study
Lancet 2006;368:647 - Abstract e diapositive
Association of bodyweight with total mortality
and with cardiovascular events in coronary artery disease: a systematic review
of cohort studie
Lancet 2006;368:666 - Abstract e diapositive
Angiotensin-converting-enzyme inhibitors in stable
vascular disease without left ventricular systolic dysfunction or heart failure:
a combined analysis of three trials
Lancet 2006;368:1096 - Abstract e diapositive
Effect of Ramipril on the Incidence of Diabetes
N
Engl J Med. 2006; [Epub ahead of print Sep] - Abstract e diapositive
Diabetes
in heart failure: prevalence and impact on outcome in the population
Am
J Med. 2006;119:591-9 - Abstract e diapositive
Coffee
consumption and risk of type 2 diabetes mellitus: an 11-year prospective study
of 28812 postmenopausal women
Arch
Intern Med. 2006;166:1311-6 - Abstract e diapositive
Meta-analysis
of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
J
Am Coll Cardiol. 2006;48:438-45 - Abstract e diapositive
Physical
activity and clustered cardiovascular risk in children: a cross-sectional study
(The European Youth Heart Study)
Lancet
2006;368:299-304 - Abstract e diapositive
Glucose
transport and sensing in the maintenance of glucose homeostasis and metabolic
harmony
J
Clin Invest. 2006 Jul;116(7):1767-75 - Abstract e diapositive
Adiponectin
and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome
J
Clin Invest. 2006 Jul;116(7):1784-92 - Abstract e diapositive
Inflammation
and insulin resistance
J
Clin Invest. 2006 Jul;116(7):1793-80 - Abstract e diapositive
Insulin
resistance and atherosclerosis
J
Clin Invest. 2006 Jul;116(7):1813-22 - Abstract e diapositive
Ghrelin
action in the brain controls dipocyte metabolism
J
Clin Invest. 2006 Jul;116(7):1983-93 - Abstract e diapositive
Efficacy
of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis
of randomised controlled trials
BMJ
2006;332(7550):1115-24 - Abstract e diapositive
Macrophage
reverse cholesterol transport: key to the regression of atherosclerosis?
Circulation
2006;113:2548-55 - Abstract e diapositive
Antihypertensive
medications and the risk of incident type 2 diabetes
Diabetes
Care 2006;29:1065-70 - Abstract e diapositive
Effect
of short-term rosuvastatin treatment on estimated glomerular filtration rate
Am
J Cardiol. 2006;97:1602-6 - Abstract e diapositive
Proteinuria,
impaired kidney function, and adverse outcomes in people with coronary disease:
analysis of a previously conducted randomised trial
BMJ.
2006 Jun 17;332(7555):online - Abstract e diapositive
Renal
function and outcome from coronary artery bypass grafting: impact on mortality
after a 2.3-year follow-up
Circulation.
2006;113:1056-62 - Abstract e diapositive
Impact
of renal dysfunction on outcomes of coronary artery bypass surgery: results from
the Society of Thoracic Surgeons National Adult Cardiac Database
Circulation.
2006;113:1063-70 - Abstract e diapositive
Efficacy
and safety of benazepril for advanced chronic renal insufficiency
N
Engl J Med. 2006;354:131-40. - Abstract e diapositive
Long-term intake of North American ginseng has no effect
on 24-hour blood pressure and renal function
Hypertension
2006;47(4):791-6 - Abstract e diapositive
Low-dose
aspirin for the prevention of atherothrombosis
N
Engl J Med 2005;353(22):2373-83 - Abstract e diapositive
Clopidogrel
and aspirin versus aspirin alone for the prevention of atherothrombotic events
N
Engl J Med 2006;354(16):1706-17 - Abstract e diapositive
Lifetime
cost of ischemic stroke in Germany: results and national projections from a population-based
stroke registry: the Erlangen Stroke Project.
Stroke
2006;37(5):1179-83 - Abstract e diapositive
Abdominal
aortic aneurysm is associated with high serum levels of tenascin-X and decreased
aneurysmal tissue tenascin-X
Circulation
2006;113(13):1702-7 - Abstract e diapositive
Non-transferrin-bound
iron and risk of coronary heart disease in postmenopausal women
Circulation
2006;113(16):1942-9 - Abstract e diapositive
Long-term
risk of mortality associated with selective and combined elevation in office,
home, and ambulatory blood pressure
Hypertension.
2006;47(5):846-53 - Abstract e diapositive
Influence
of HDL cholesterol on preclinical carotid atherosclerosis in familial hypercholesterolemia
ATVB
2006 May;26(5):1107-13 - Abstract e diapositive
Differential
healing activities of CD34+ and CD14+ endothelial cell progenitors
ATVB
2006 Apr;26(4):758-64 - Abstract e diapositive
Decreased
high-density lipoprotein (HDL) particle size, prebeta-, and large HDL subspecies
concentration in Finnish low-HDL families: relationship with intima-media thickness
ATVB
2006 Apr;26(4):897-902 - Abstract e diapositive
Thrombomodulin
gene polymorphisms and haplotypes and the risk of cardiovascular events: a prospective
follow-up study
ATVB
2006 Apr;26(4):942-7 - Abstract e diapositive
Oxidative stress and vascular disease: 2005 Duff lecture
ATVB
2006 Apr;26(4):689-95 - Abstract e diapositive
Modulation
of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha
activators: clinical and experimental evidence
ATVB
2006 May;26(5):977-86 - Abstract e diapositive
Dietary
factors that promote or retard inflammation
ATVB
2006 May;26(5):995-100 - Abstract e diapositive
Reciprocal
relationships between insulin resistance and endothelial dysfunction: molecular
and pathophysiological mechanisms
Circulation.
2006 Apr 18;113(15):1888-904 - Abstract e diapositive
Homocysteine
lowering with folic acid and B vitamins in vascular disease
N
Engl J Med. 2006;354:1567-77. - Abstract e diapositive
Homocysteine
lowering and cardiovascular events after acute myocardial infarction
N
Engl J Med. 2006;354:1578-88 - Abstract e diapositive
Homocysteine
Trials - Clear Outcomes for Complex Reasons
N
Engl J Med. 2006;354:1629-328 - Editoriale e diapositive
Trans fatty
acids and cardiovascular disease
N
Engl J Med. 2006;354:1601-13 - Abstract e diapositive
Low-density lipoprotein and high-density lipoprotein particle subclasses predict
coronary events and are favorably changed by gemfibrozil therapy in the Veterans
Affairs High-Density Lipoprotein Intervention Trial
Circulation.
2006;113:1556-63. - Abstract e diapositive
Relationship
between homocysteine and mortality in chronic kidney disease
Circulation.
2006;113:1572-7 - Abstract e diapositive
Type
1 diabetes
Lancet.
2006;367:847-58 - Abstract e diapositive
Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and
cancer: systematic review
BMJ.
2006 Mar 24; [Epub ahead of print] - Abstract e diapositive
Effect
of ACAT inhibition on the progression of coronary atherosclerosis
N
Engl J Med; 354(12):1253-63. - Abstract e diapositive
Sequence
variations in PCSK9, low LDL, and protection against coronary heart disease
N
Engl J Med;354(12):1264-72. - Abstract e diapositive
Effect
of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis:
The ASTEROID Trial
JAMA
2006;295: Epub ahead of print - Abstract e diapositive
Intensive
Lipid Lowering With Atorvastatin Is Associated With a Significant Improvement
in Renal Function: The Treating to New Targets (TNT) Study
ACC,
55th Annual Scientific Session - Abstract e diapositive
Soy
protein, isoflavones, and cardiovascular health: an American Heart Association
Science Advisory for professionals from the Nutrition Committee
Circulation.
2006;113:1034-44 - Abstract e diapositive
Effect
of intensive versus standard lipid-lowering treatment with atorvastatin on the
progression of calcified coronary atherosclerosis over 12 months: a multicenter,
randomized, double-blind trial
Circulation.
2006;13:427-37 - Abstract e diapositive
Long-term
outcome of renal transplantation from older donors
N
Engl J Med. 2006;354:343-52 - Abstract e diapositive
Does
apolipoprotein E genotype influence the risk of ischemic stroke, intracerebral
hemorrhage, or subarachnoid hemorrhage? Systematic review and meta-analyses of
31 studies among 5961 cases and 17,965 controls
Stroke.
2006;37:364-70 - Abstract e diapositive
Relationship
between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study
Circulation
2006 Jan 3;113: 38-43 - Abstract e diapositive
Effects
of omega-3 fatty acids on cancer risk: a systematic review
JAMA.
2006 Jan 25;295(4):403-15 - Abstract e diapositive
Statins
and sepsis in patients with cardiovascular disease: a population-based cohort
analysis
Lancet.
2006 Feb 4;367(9508):413-8 - Abstract e diapositive
Aspirin
resistance
Lancet.
Published Online January 24,2006 - Abstract e diapositive
Prediction
of coronary heart disease by erectile dysfunction in men referred for nuclear
stress testing
Arch
Intern Med. 2006;166(2):201-6 - Abstract e diapositive
Predictors
and prevalence of erectile dysfunction in a racially diverse population
Arch
Intern Med. 2006;166(2):207-12 - Abstract e diapositive
The
prevalence of erectile dysfunction in the primary care setting: importance of
risk factors for diabetes and vascular disease
Arch
Intern Med. 2006;166(2):213-9 - Abstract e diapositive
Mortality
and cardiovascular risk across the ankle-arm index spectrum: results from the
Cardiovascular Health Study
Circulation.
2006;113(3):388-93 - Abstract e diapositive
A prospective study of plasma lipid levels and hypertension in women
Arch
Intern Med. 2005;165:2420-7 - Abstract e diapositive
Excess
risk of fatal coronary heart disease associated with diabetes in men and women:
meta-analysis of 37 prospective cohort studies
BMJ.
2006;332(7533):73-8. - Abstract e diapositive
Temporal
trends in the utilization of diagnostic testing and treatments for cardiovascular
disease in the United States, 1993-2001
Circulation.
2006;113:374-9. - Abstract e diapositive
Proliferation of cardiac technology in Canada: a challenge
to the sustainability of Medicare
Circulation.
2006;113:380-7. - Abstract e diapositive
Dyslipidemia
and the risk of incident hypertension in men
Hypertension.
2006;47:45-50 - Abstract e diapositive
Aspirin for the primary prevention
of cardiovascular events in women and men: a sex-specific meta-analysis of randomized
controlled trials
JAMA.
2006;295:306-13 - Abstract e diapositive
Statins and cancer risk: a meta-analysis
JAMA.
2006;295:74-80 - Abstract e diapositive
Serum lipids, lipid-lowering drugs, and the risk of breast cancer
Arch
Intern Med. 2005;165:2264-71 - Abstract e diapositive
Preventing chronic diseases: how many
lives can we save?
Lancet.
2005;366:1578-82 - Abstract e diapositive
C-reactive protein and its role in
metabolic syndrome: mendelian randomisation study
Lancet.
2005;366:1954-9 - Abstract e diapositive
Nature's randomised trials
Lancet.
2005;366:1906-8 - Editoriale e diapositive
Adherence
to candesartan and placebo and outcomes in chronic heart failure in the CHARM
programme: double-blind, randomised, controlled clinical trial
Lancet.
2005;366:2005-11 - Abstract e diapositive
Adherence
and outcomes: it's more than taking the pills
Lancet.
2005;366:1989-91 - editoriale
Non–High-Density
Lipoprotein Cholesterol and Apolipoprotein B in the Prediction of Coronary Heart
Disease in Men
Circulation
2005; 112: 3375-3383 - Abstract e diapositive
Apolipoprotein
B Versus Non–High-Density Lipoprotein Cholesterol. And the Winner Is. . .
Circulation
2005; 112: 3366-3367 - Editoriale
Weighing
in Before the Fight
LDL
Cholesterol and Non–HDL Cholesterol Versus Apolipoprotein B as the Best Predictor
for Coronary Heart Disease and the Best Measure of Therapy
Circulation
2005; 112: 3368-3370 - Editoriale
Pleiotropic
Effects of Statins: Benefit Beyond Cholesterol Reduction?
- A meta-regression analysis
J
Am Coll Cardiol. 2005; 46:1855-62 - Abstract e diapositive
Obesity
and the risk of myocardial infarction in 27,000 participants from 52 countries:
a case-control study.
Lancet.
2005 Nov 5;366(9497):1640-9 - Abstract e diapositive
Randomized
trial of lifestyle modification and pharmacotherapy for obesity
N
Engl J Med. 2005 Nov 17;353(20):2111-20 - Abstract e diapositive
Effects
of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
N
Engl J Med. 2005 Nov 17;353(20):2121-34 - Abstract e diapositive
Plasma
lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment
benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)
Circulation
2005;112:3058-65 - Abstract e diapositive
Effects
of long-term fenofibrate therapy on cardiovascular events in 9795 people with
type 2 diabetes mellitus (the FIELD study): randomised controlled trial
The
Lancet Early Online Publication - Abstract e diapositive
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After
Myocardial Infarction The IDEAL Study: A Randomized Controlled Trial
JAMA.
2005;294:2437-2445 - Abstract e diapositive
Tendon
xanthomas in familial hypercholesterolemia are associated with cardiovascular
risk independently of the low-density lipoprotein receptor gene mutation.
Arterioscler
Thromb Vasc Biol. 2005; 25:1960-5 - Abstract e diapositive
Elevated
high-density lipoprotein cholesterol levels are protective against plaque progression:
a follow-up study of 1952 persons with carotid atherosclerosis the Tromso study
Circulation.
2005; 112: 498-504 - Abstract e diapositive
Cyclooxygenase
inhibition and cardiovascular risk
Circulation.
2005; 112: 759-70 - Abstract e diapositive
Carotid
intima-media thickness, plaques, and framingham risk score as independent determinants
of stroke risk
Stroke.
2005; 36: 1741-5 - Abstract e diapositive
The
PROactive study:some answers, many questions
Lancet.
2005;366:1241 - Editoriale e diapositive
Secondary
prevention of macrovascular events in patients with type 2 diabetes in the PROactive
Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised
controlled trial
Lancet.
2005;366:1279-89 - Abstract e diapositive
Efficacy
and safety of cholesterol-lowering treatment: prospective meta-analysis of data
from 90,056 participants in 14 randomised trials of statins
Lancet.
2005;366:1267-782 - Abstract e diapositive
Diagnosis
and Management of the Metabolic Syndrome
Circulation
2005; Pub online September 12, - Full text e diapositive
Are
the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled
trials of homoeopathy and allopathy
Lancet.
2005;366:726-32 - Abstract e diapositive
Circulating
endothelial progenitor cells and cardiovascular outcomes
N
Engl J Med. 2005;353:999-1007- Abstract e diapositive
Metabolic
Syndrome: A Misleading ‘Diagnosis’
Joint
European/ADA Paper Asks for Clearer Definition, More Research
Effect
of lowering of homocysteine levels on inflammatory markers: a randomized controlled
trial
Arch
Intern Med. 2005;165(12):1388-94. - Abstract e diapositive
Associations
of serum IL-18 levels with carotid intima-media thickness
ATVB
2005;25(7):1458-62 - Abstract e diapositive
Statin
therapy may be associated with lower mortality in patients with diastolic heart
failure: a preliminary report
Circ
2005;112(3):357-63 - Abstract e diapositive
Fish
consumption among healthy adults is associated with decreased levels of inflammatory
markers related to cardiovascular disease: the ATTICA study
J
Am Coll Cardiol. 2005;46(1):120-4 - Abstract e diapositive
A
simple score (ABCD) to identify individuals at high early risk of stroke after
transient ischaemic attack
Lancet.
2005 Jul 2;366(9479):29-36 - Abstract e diapositive
C-reactive
protein-induced in vitro endothelial cell activation is an artefact caused by
azide and lipopolysaccharide
ATVB
2005;25(6):1225-30 - Abstract e diapositive
Binding
and internalization of C-reactive protein by Fcgamma receptors on human aortic
endothelial cells mediates biological effects
ATVB
2005;25(7):1359-63 - Abstract e diapositive
Cholesterol
feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive
subjects
Circ
2005;111(23):3058-62 - Abstract e diapositive
C-reactive
protein and the 10-year incidence of coronary heart disease in older men and women:
the cardiovascular health study
Circ
2005;112(1):25-31 - Abstract e diapositive
Transgenic
human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice
PNAS
2005;102(23):8309-14 - Abstract e diapositive
Effects of antibiotic therapy on outcomes of patients with coronary artery disease:
a meta-analysis of randomized controlled trials
JAMA.
2005;293:2641-7 - Abstract e diapositive
Effect
of VKORC1 haplotypes on transcriptional regulation and warfarin dose
N
Engl J Med 2005;352:2285-93 - Abstract e diapositive
Atorvastatin
in patients with type 2 diabetes mellitus undergoing hemodialysis
N
Engl J Med 2005;353:238-48 - Abstract e diapositive
National
trends in statin use by coronary heart disease risk category
PLoS
Med 2005;2:e123 - Abstract e diapositive
COX
2 inhibitors, traditional NSAIDs, and the heart
BMJ
2005;330:1342-1343 - Editoriale
Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors
or conventional non-steroidal anti-inflammatory drugs: population based nested
case-control analysis
BMJ
2005 330: 1366. - Abstract e diapositive
Differences
in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib,
or non-steroidal anti-inflammatory drugs: population based study
BMJ
2005 330: 1370. - Abstract e diapositive
A Role for Oxidized Phospholipids in Atherosclerosis
N
Engl J Med. 2005;353:9 - Editoriale
Oxidized phospholipids, Lp(a) lipoprotein, and coronary
artery disease
N
Engl J Med. 2005 Jul 7;353(1):46-57 - Abstract e diapositive
Cystatin C and the risk of death and cardiovascular events
among elderly persons
N
Engl J Med. 2005 May 19;352(20):2049-60 - Abstract e diapositive
Vitamin E and donepezil for the treatment of mild cognitive
impairment.
N
Engl J Med. 2005 Jun 9;352(23):2379-88 - Abstract e diapositive
Torcetrapib
and Atorvastatin - Should Marketing Drive the Research Agenda?
N
Engl J Med. 2005;352:2573 - Full text
The
Lessons of Vioxx - Drug Safety and Sales
N
Engl J Med. 2005;352:2576 - Full text
Diabetes enhances vulnerability to particulate air pollution-associated impairment
in vascular reactivity and endothelial function
Circulation.
2005 Jun 7;111(22):2913-20 - Abstract e diapositive
Statins and the risk of colorectal cancer
N
Engl J Med. 2005 May 26;352(21):2184-92 - Abstract e diapositive
Effects
of long-term vitamin E supplementation on cardiovascular events and cancer: a
randomized controlled trial.
JAMA.
2005 Mar 16;293(11):1338-47 - Abstract e diapositive
A randomized
trial of intensive lipid-lowering therapy in calcific aortic stenosis
N
Engl J Med. 2005 Jun 9;352(23):2389-97- Abstract e diapositive
The Issue of Statin Safety Where do We Stand?
Circulation.
2005;111:3016-3019 Editoriale
The Safety of Rosuvastatin as Used in Common Clinical Practice.
A Postmarketing Analysis
Circulation.
2005; 111:3051 - Abstract e diapositive
Relationship
of office, home, and ambulatory blood pressure to blood glucose and lipid variables
in the PAMELA population
Hypertension.
2005;45:1072-7-Abstract e diapositive
Cost-effectiveness
of simvastatin in people at different levels of vascular disease risk: economic
analysis of a randomised trial in 20,536 individuals.
Lancet.
2005 May;365:1779-85. Abstract e diapositive
Plasma levels of soluble receptor for advanced glycation
end products and coronary artery disease in nondiabetic men
Arterioscler
Thromb Vasc Biol. 2005; 25: 1032-74. Abstract e diapositive
Effectiveness of statins for secondary prevention in elderly
patients after acute myocardial infarction: an evaluation of class effect
CCMAJ.
2005 Apr 26;172(9):1187-94 - Abstract e diapositive
Decreased
histone deacetylase activity in chronic obstructive pulmonary disease
N
Engl J Med. 2005 May 12;352(19):1967-76 - Abstract e diapositive
Management
of depression after stroke: a systematic review of pharmacological therapies
Arterioscler
Thromb Vasc Biol. 2005; 25: 1032-74. Abstract e diapositive
Metabolic
syndrome: a comprehensive perspective based on interactions between obesity, diabetes,
and inflammation
Circulation.
2005 Mar 22;111(11):1448-54. Abstract e diapositive
Simvastatin versus ezetimibe: pleiotropic and lipid-lowering
effects on endothelial function in humans
Circulation.
2005 May 10;111(18):2356-63 - Abstract e diapositive
Reduction
in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes:
Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA)
Diabetes
Care. 2005 May;28(5):1151-7 Abstract e diapositive
Effects
of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular
risk factors in overweight patients: 1-year experience from the RIO-Europe study
Lancet.
2005 Apr;365(9468):1389-97 Abstract e diapositive
Fighting
obesity and associated risk factors by antagonising cannabinoid type 1 receptors
Lancet.
2005 Apr;365(9468):1363 - Editoriale
Azithromycin
for the secondary prevention of coronary events
N
Engl J Med. 2005;352:1637-45 - Abstract e diapositive
Antibiotic
treatment of Chlamydia pneumoniae after acute coronary syndrome
N
Engl J Med. 2005;352:1645-54 - Abstract e diapositive
Inflammation,
atherosclerosis, and coronary artery disease
N
Engl J Med. 2005;352:1685-95 - Abstract e diapositive
QTc
prolongation by grapefruit juice and its potential pharmacological basis: HERG
channel blockade by flavonoids
Circulation
2005;111:835 - Abstract e diapositive
White
blood cell count predicts reduction in coronary heart disease mortality with pravastatin
Circulation
2005;111:1756 - Abstract e diapositive
Plasma triglycerides and type
III hyperlipidemia are independently associated with premature familial coronary
artery disease
J
Am Coll Cardiol 2005;45:1003 - Abstract e diapositive
COX-2
inhibitors - a lesson in unexpected problems
N Engl J Med. 2005;352:1131 - Abstract
Cardiovascular risk associated
with celecoxib in a clinical trial for colorectal adenoma prevention
N Engl J Med. 2005;352:1071
- Abstract
e diapositive
Complications of the COX-2 inhibitors parecoxib and valdecoxib
after cardiac surgery
N
Engl J Med. 2005;352:1081 - Abstract
e diapositive
Cardiovascular events associated with rofecoxib in a
colorectal adenoma chemoprevention trial
N
Engl J Med. 2005 Mar 17;352(11):1092 - Abstract
e diapositive
Predictors
of new-onset diastolic and systolic hypertension: the Framingham Heart Study
Circulation 2005; 111: 1121
- Abstract
e diapositive
Plaque
instability frequently occurs days or weeks before occlusive coronary thrombosis:
a pathological thrombectomy study in primary percutaneous coronary intervention
Circulation
2005; 111: 1160 - Abstract
e diapositive
A Randomized Trial of Low-Dose Aspirin in the Primary
Prevention of Cardiovascular Disease in Women
N
Engl J Med 2005 Mar-7; [Epub] - Abstract
e diapositive
Intensive Lipid Lowering with Atorvastatin
in Patients with Stable Coronary Disease
N
Engl J Med 2005 Mar-8; [Epub] - Abstract
e diapositive
Predictors
of new-onset diastolic and systolic hypertension: the Framingham Heart Study
Circulation 2005; 111: 1121 - Abstract
e diapositive
Plaque
instability frequently occurs days or weeks before occlusive coronary thrombosis:
a pathological thrombectomy study in primary percutaneous coronary intervention
Circulation 2005; 111: 1160 - Abstract
e diapositive
A
Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular
Disease in Women
N Engl J Med 2005 Mar-7; [Epub] - Abstract
e diapositive
Intensive
Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
N Engl J Med 2005 Mar-8; [Epub] - Abstract
e diapositive
La Food and Drug Amministration si pronuncia su Rosuvastatina
rispetto alle richieste di Public Citizen
http://www.fda.gov/cder/drug/infopage/rosuvastatin/crestor_CP.pdf
Resistin is an inflammatory marker of atherosclerosis in humans
Reilly
MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ
Circulation
2005;111:932-9. - Abstract
e diapositive
N-terminal
pro-B-type natriuretic peptide and long-term mortality in stable coronary heart
disease
Kragelund
C, Gronning B, Kober L, Hildebrandt P, Steffensen R
N
Engl J Med. 2005; 352: 666-75 - Abstract
e diapositive
Il
Comitato degli Esperti della FDA raccomanda la permanenza in commercio degli inibitori
Cox-2 ed il ritorno di Rofecoxib sul mercato
Abstract
Short-Term
Treatment With Atorvastatin Reduces Platelet CD40 Ligand and Thrombin Generation
in Hypercholesterolemic Patients
Valerio Sanguigni, Pasquale
Pignatelli, Luisa Lenti, Domenico Ferro, Alfonso Bellia, Roberto Carnevale, Manfredi
Tesauro, Roberto Sorge, Renato Lauro, Francesco Violi
Circulation.
2005;111:412-419 - Abstract
e diapositive
Effects
of moderate alcohol consumption on cognitive function in women
Stampfer MJ, Kang JH, Chen
J, Cherry R, Grodstein F
N
Engl J Med. 2005 Jan 20;352(3):245-53 - Abstract
e diapositive
Vascular
risk factors and diabetic neuropathy
Tesfaye
S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR, Fuller
JH; EURODIAB Prospective Complications Study Group
N
Engl J Med. 2005 Jan 27;352(4):341-50 - Abstract e diapositive
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric
surgery
Sjostrom
L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson
B, Narbro K, Sjostrom CD, Sullivan M, Wedel H; Swedish Obese Subjects Study Scientific
Group
N
Engl J Med. 2004 Dec 23;351(26):2683-93 - Abstract e diapositive
Adiposity
as compared with physical activity in predicting mortality among women
Hu
FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JE
N
Engl J Med. 2004 Dec 23;351(26):2694-703 - Abstract e diapositive
Cardiovascular
toxicity of valdecoxib
Ray
WA, Griffin MR, Stein CM
N
Engl J Med. 2004 Dec 23;351(26):2767 - Full text
Nuovi
aggiornamenti relativi alla Nota 13
Effect
of antihypertensive agents on cardiovascular events in patients with coronary
disease and normal blood pressure: the CAMELOT study: a randomized controlled
trial
Nissen
SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf
E, Topol EJ; CAMELOT Investigators.
JAMA
2004;292:2217-25 - Abstract e diapositive
Risk
of myocardial infarction and stroke after acute infection or vaccination
Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P.
N
Engl J Med 2004;351:2611-8 - Abstract e diapositive
Inflammatory
markers and the risk of coronary heart disease in men and women
Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan
GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB.
N
Engl J Med 2004;351:2599-610 - Abstract e diapositive
Statins in stroke prevention and carotid atherosclerosis:
systematic review and up-to-date meta-analysis
Amarenco
P, Labreuche J, Lavallee P, Touboul PJ.
Stroke
2004;35:2902-9 - Abstract e diapositive
Notizia
ANSA relativa alla NOTA 13
Statine
e rabdomiolisi: una analisi di popolazione: Incidence
of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH,
Chan KA, Goodman MJ, Platt R.
JAMA.
2004 Dec 1;292(21):2585-90 - Abstract e diapositive.
L'acido
Nicotinico riduce la progressione dell'inspessimento carotideo: Arterial
Biology for the Investigation of the Treatment Effects of Reducing Cholesterol
(ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin
on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins
Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA
Circulation
2004 Dec 7;110(23):3512-7 - Abstract e diapositive.
ACE
inibitori e CAD: Angiotensin-converting-enzyme
inhibition in stable coronary artery disease
Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA,
Rice MM, Rosenberg YD, Rouleau JL; PEACE Trial Investigators
N
Engl J Med. 2004 Nov 11;351(20):2058-68 - Abstract.
Vitamina
E: Attenzione alle alte dosi: Meta-Analysis:
High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E
Ann
Intern Med. 2004 Nov 10; [Epub ahead of print] - Abstract e diapositive.
Exposure
to traffic and the onset of myocardial infarction
Peters A, von Klot S, Heier M, Trentinaglia I, Hormann A, Wichmann HE, Lowel H;
Cooperative Health Research in the Region of Augsburg Study Group.
N
Engl J Med. 2004 Oct 21;351(17):1721-30 - Abstract e diapositive.
Preventing
microalbuminuria in type 2 diabetes
Ruggenenti
P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi
F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini
AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators
N
Engl J Med. 2004 Nov 4;351(19):1941-51 - Abstract e diapositive
Relation
between renal dysfunction and cardiovascular outcomes after myocardial infarction
Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White
HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf
RM, Pfeffer MA.
N
Engl J Med. 2004 Sep 23;351(13):1285-95 - Abstract e diapositive.
Chronic
kidney disease and the risks of death, cardiovascular events, and hospitalization
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY
N
Engl J Med. 2004 Sep 23;351(13):1296-305 - Abstract e diapositive.
CONSIDERAZIONI
SULLA SICUREZZA D'USO DEI COXIB
Failing the Public Health - Rofecoxib,Merck,and the FDA
Eric
J.Topol - NEJM 2004;351:1707
Coxibs and Cardiovascular Disease
Garret
A.FitzGerald - NEJM 2004;351:1709
Obbligatorio registrare i trials clinici per poterli pubblicare
Clinical Trial Registration: A Statement from the International Committee of Medical
Journal Editors
Disponibile
il PDF completo dell'articolo
Effect
of potentially modifiable risk factors associated with myocardial infarction in
52 countries (the INTERHEART study): case-control study
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais
P, Varigos J, Lisheng L; INTERHEART Study Investigators
Lancet.
2004 Sep 11; 364(9438): 937-52 - Abstract
Primary
prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the
Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled
trial
Helen M Colhoun, D John Betteridge, Paul N Durrington, Graham
A Hitman, H Andrew W Neil, Shona J Livingstone, Margaret J Thomason, Michael I
Mackness, Valentine Charlton-Menys, John H Fuller, on behalf of the CARDS investigators
Lancet
2004; 364:685-96 - Abstract
Mortality
and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin
Survival Study (4S)
Timo
E Strandberg, Kalevi Pyörälä ,Thomas J Cook, Lars Wilhelmsen, Ole
Faergeman, Gudmundur Thorgeirsson, Terje R Pedersen, John Kjekshus, for the 4S
Group
Lancet
2004;364:771-77 - E' disponibile il PDF completo dell'articolo.
Reduction of cardiovascular
events by simvastatin in nondiabetic coronary heart disease patients with and
without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin
Survival Study (4S).
Pyorala K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, Mitchel YB, Pedersen
TR, Kjekshus J; Scandinavian Simvastatin Survival Study (4S).
Diabetes
Care. 2004 Jul;27(7):1735-40 - Abstract.
Fish
intake and risk of incident atrial fibrillation.
Mozaffarian
D, Psaty BM, Rimm EB, Lemaitre RN, Burke GL, Lyles MF, Lefkowitz D, Siscovick
DS.
Circulation.
2004 Jul 27;110(4):368-73. Epub 2004 Jul 19 - Abstract.
Effect
of atorvastatin on risk of recurrent cardiovascular events after an acute coronary
syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction
with Aggressive Cholesterol Lowering (MIRACL) Study
Kinlay
S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, Ganz P, Libby P; Myocardial
Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators
Circulation.
2004 Jul 27;110(4):386-91. Epub 2004 Jul 19 - Abstract.